Classifications

• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
  • C12N15/102—Mutagenizing nucleic acids
  • C12N15/1031—Mutagenizing nucleic acids mutagenesis by gene assembly, e.g. assembly by oligonucleotide extension PCR
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
  • C12N15/1034—Isolating an individual clone by screening libraries
  • C12N15/1058—Directional evolution of libraries, e.g. evolution of libraries is achieved by mutagenesis and screening or selection of mixed population of organisms
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/52—Genes encoding for enzymes or proenzymes
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
  • C12N15/66—General methods for inserting a gene into a vector to form a recombinant vector using cleavage and ligation; Use of non-functional linkers or adaptors, e.g. linkers containing the sequence for a restriction endonuclease

Definitions

• the invention provides strategies, methods, vectors, reagents, and systems for production of synthetic genes, production of libraries of such genes, and manipulation and characterization of the genes and corresponding encoded polypeptides.
• the synthetic genes can encode polyketide synthase polypeptides and facilitate production of therapeutically or commercially important polyketide compounds.
• the invention finds application in the fields of human and veterinary medicine, pharmacology, agriculture, and molecular biology.
• Polyketides represent a large family of compounds produced by fungi, mycelial bacteria, and other organisms. Numerous polyketides have therapeutically relevant and/or commercially valuable activities. Examples of useful polyketides include erythromycin, FK- 506, FK-520, megalomycin, narbomycin, oleandomycin, picromycin, rapamycin, spinocyn, and tylosin.
• Polyketides are synthesized in nature from 2-carbon units through a series of condensations and subsequent modifications by polyketide synthases (PKSs).
• PKSs polyketide synthases
• Polyketide synthases are multifunctional enzyme complexes composed of multiple large polypeptides. Each of the polypeptide components of the complex is encoded by a separate open reading frame, with the open reading frames corresponding to a particular PKS typically being clustered together on the chromosome.
• PKSs polyketide synthases
• PKS polypeptides comprise numerous enzymatic and carrier domains, including acyltransferase (AT), acyl carrier protein (ACP), and beta-ketoacylsynthase (KS) activities, involved in loading and condensation steps; ketoreductase (KR), dehydratase (DH), and enoylreductase (ER) activities, involved in modification at ⁇ -carbon positions of the growing chain, and thioesterase (TE) activities involved in release of the polyketide from the PKS.
• AT acyltransferase
• ACP acyl carrier protein
• KS beta-ketoacylsynthase
• KR ketoreductase
• DH dehydratase
• ER enoylreductase
• TE thioesterase
• modules the 6-deoxyerythronolide B synthase
• DEBS 6-deoxyerythronolide B synthase
• the number, sequence, and domain content of the modules of a PKS determine the structure of the polyketide product of the PKS.
• Properties of polyketide synthase domains are well known (see, e.g., Donadio and Katz, 1992, "Organization of the enzymatic domains in the multifunctional polyketide synthase involved in erythromycin formation in Saccharopolyspora erythraea.” Gene 111 :51-60).
• the technology also allows one to produce molecules that are structurally related to, but distinct from, the polyketides produced from known PKS gene clusters by inactivating a domain in the PKS and/or by adding a domain not normally found in the PKS though manipulation of the PKS gene.
• PKS enzymes function While the detailed understanding of the mechanisms by which PKS enzymes function and the development of methods for manipulating PKS genes have facilitated the creation of novel polyketides, there are presently limits to the creation of novel polyketides by genetic engineering. One such limit is the availability of PKS genes. Many polyketides are known but only a relatively small portion of the corresponding PKS genes have been cloned and are available for manipulation.
• the invention provides a synthetic gene encoding a polypeptide segment that corresponds to a reference polypeptide segment encoded by a naturally occurring gene.
• the polypeptide segment-encoding sequence of the synthetic gene is different from the polypeptide segment-encoding sequence of the naturally occurring gene.
• the polypeptide segment-encoding sequence of the synthetic gene is less than about 90% identical to the polypeptide segment-encoding sequence of the naturally occurring gene, or in some embodiments, less than about 85% or less than about 80% identical.
• the polypeptide segment-encoding sequence of the synthetic gene comprises at least one (and in other embodiments, more than one, e.g., at least two, at least three, or at least four) unique endonuclease (e.g., restriction endonuclease) sites that are not present or are not unique in the polypeptide segment-encoding sequence of the naturally occurring gene.
• the polypeptide segment-encoding sequence of the synthetic gene is free from at least one endonuclease (e.g., restriction endonuclease) site that is present in the polypeptide segment-encoding sequence of the naturally occurring gene.
• the polypeptide segment encoded by the synthetic gene corresponds to at least 50 contiguous amino acid residues encoded by the naturally occurring gene.
• the polypeptide segment is from a polyketide synthase (PKS) and may be or include a PKS domain (e.g., AT, ACP, KS, KR, DH, ER, and/or TE) or one or more PKS modules.
• PKS polyketide synthase
• the polypeptide segment-encoding sequence of the synthetic gene is free from at least one Type IIS or Type US-like enzyme restriction site (e.g., Bci NI, Bmr I, Bpm I, Bpu El, Bse Rl, Bsg I, Bsr Di, Bts I, Eci I, Ear I, Sap I, Bsm Bl, Bsp MI, Bsa I, Bbs I, Bfu Al, Fok I and Alw I) present in the polypeptide segment-encoding sequence of the naturally occurring gene.
• Type IIS or Type US-like enzyme restriction site e.g., Bci NI, Bmr I, Bpm I, Bpu El, Bse Rl, Bsg I, Bsr Di, Bts I, Eci I, Ear I, Sap I, Bsm Bl, Bsp MI, Bsa I, Bbs I, Bfu Al, Fok I and Alw I
• the invention provides a synthetic gene encoding a polypeptide segment that corresponds to a reference polypeptide segment encoded by a naturally occurring PKS gene, where the polypeptide segment-encoding sequence of the synthetic gene is different from the polypeptide segment encoding sequence of the naturally occurring PKS gene and comprises at least two of (a) a Spe I site near the sequence encoding the amino-terminus of a module; (b) a Mfe I site near the sequence encoding the amino- terminus of a KS domain; (c) a Kpn I site near the sequence encoding the carboxy-terminus of a KS domain; (d) a Msc I site near the sequence encoding the amino-terminus of an AT domain; (e) a Pst I site near the sequence encoding the carboxy-terminus of an AT domain; (f) a Bsr Bl site near the sequence encoding the amino-terminus of an ER domain; (g) an Age I
• the invention provides a vector (e.g., cloning or expression vector) comprising a synthetic gene of the invention.
• the vector comprises an open reading frame encoding a first PKS module and one or more of (a) a PKS extension module; (b) a PKS loading module; (c) a releasing (e.g., thioesterase) domain; and (d) an interpolypeptide linker.
• Cells that comprise and optionally express a gene or vector of the invention are provided, as well as a cell comprising a polypeptide encoded by the vector. Also provided are cells that express, a functional polyketide synthase that comprises a polypeptide encoded by the vector.
• a PKS polypeptide having a non-natural amino sequence is provided, such as a polypeptide characterized by a KS domain comprising the dipeptide Leu- Gln at the carboxy-terminal edge of the domain; and/or an ACP domain comprising the dipeptide Ser-Ser at the carboxy-terminal edge of the domain.
• a method is provided for making a polyketide comprising culturing a cell comprising a synthetic DNA of the invention under conditions in which a polyketide is produced, wherein the polyketide would not be produced by the cell in the absence of the vector.
• the invention provides gene libraries.
• a gene library is provided that contains a plurality of different PKS module-encoding genes, where the module-encoding genes in the library have at least one (or more than one, such as at least 3, at least 4, at least 5 or at least 6) restriction site(s) in common, the restriction site is found no more than one time in each module, and the modules encoded in the library correspond to modules from five or more different polyketide synthase proteins.
• the restriction site(s) is selected from Spe I, Mfe I, Afi II, Bsi WI, Sac II, Ngo MIN, ⁇ he I, Kpn I, Msc I, Bgl II, Bss HII, Sac II, Age I, Pst I, Bsr Bl, Kas I, Mlu I, Xba I, Sph I, Bsp E, and ⁇ go MIN recognition sites.
• the restriction site in common is a Spe I site near the sequence encoding the amino-termini of the modules; a Mfe I site near the sequence encoding the amino-termini of KS domains; a Kpn I site near the sequence encoding the carboxy-termini of KS domains; a Msc I site near the sequence encoding the amino-termini of AT domains; a Pst I site near the sequence encoding the carboxy-termini of AT domains; a BsrB I site near the sequence encoding the amino-termini of ER domains; an Age I site near the sequence encoding the amino-termini of KR domains; and/or an Xba I site near the sequence encoding the amino-termini of ACP domains.
• Vectors for gene libraries include cloning and expression vectors.
• a library includes open reading frames that contain an extension module and at least one of a second PKS extension module, a PKS loading module, a thioesterase domain, and an interpolypeptide linker.
• the invention provides a method for synthesis of an expression library of PKS module-encoding genes by making a plurality of different PKS module- encoding genes as described above and cloning each gene into an expression vector.
• the library may include, for example, at least about 50 or at least about 100 different module- encoding genes.
• compositions of a vector and a Type IIS or Type US-like or other endonuclease (e.g., restriction) enzyme that recognizes a site on the vector compositions comprising cognate pairs of vectors, kits, and the like.
• the invention provides a vector comprising a first selectable marker, endonuclease (e.g., restriction) site (Ri) recognized by a first endonuclease (e.g., restriction enzyme), and a synthon coding region that is flanked by a restriction site recognized by a first Type IIS or Type US-like restriction enzyme and a restriction site recognized by a second Type IIS or Type US-like restriction enzyme, wherein digestion of the vector with the endonuclease recognizing Ri and the first Type IIS or Type US-like restriction enzyme produces a fragment comprising the first selectable marker and the synthon coding region, and digestion of the vector with the endonuclease recognizing R ⁇ and the second Type IIS or Type US-like restriction enzyme produces a fragment comprising the synthon coding region and not comprising the first selectable marker.
• endonuclease e.g., restriction
• Ri endonuclease
• a synthon coding region that is flanked by
• the vector comprising a second selectable marker wherein digestion of the vector with the first endonuclease (e.g., restriction enzyme) and the first Type IIS or Type US-like restriction enzyme produces a fragment comprising the first selectable marker and the synthon coding region, and not comprising the second selectable marker, digestion of the vector with the first endonuclease (e.g., restriction enzyme) and the second Type IIS or Type US-like restriction enzyme produces a fragment comprising the second selectable marker and the synthon coding region, and not comprising the first selectable marker.
• the first endonuclease e.g., restriction enzyme
• the second Type IIS or Type US-like restriction enzyme produces a fragment comprising the second selectable marker and the synthon coding region, and not comprising the first selectable marker.
• the invention provides methods of stitching adjacent DNA units (synthons) to synthesize a larger unit.
• the invention provides a method for making a synthetic gene encoding a PKS module by producing a plurality (i.e., at least 3) of DNA units by assembly PCR, wherein each DNA unit encodes a portion of the PKS module and combining the plurality of DNA units in a predetermined sequence to produce PKS module- encoding gene.
• the method includes combining the module-encoding gene in-frame with a nucleotide sequence encoding a PKS extension module, a PKS loading module, a thioesterase domain, or an PKS interpolypeptide linker, to produce a PKS open reading frame.
• the invention provides a method for joining a series of DNA units using a vector pair by (a) providing a first set of DNA units, each in a first-type selectable vector comprising a first selectable marker and providing a second set of DNA units, each in a second-type selectable vector comprising a second selectable marker different from the first, wherein the first-type and second-type selectable vectors can be selected based on the different selectable markers, (b) recombinantly joining a DNA unit from the first set with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a third DNA unit, and obtaining a desired clone by selecting for the first selectable marker (c) recombinantly joining the third DNA unit with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the first selectable marker, or recombinantly joining the third DNA unit with
• the step (c) comprises recombinantly joining the third DNA unit with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a fourth DNA unit, and obtaining a desired clone by selecting for the first selectable marker, the method further comprising recombinantly combining the fourth DNA unit with an adjacent DNA unit from the second set to generate a first-type selectable vector comprising a fifth DNA unit, and obtaining a desired clone by selecting for the first selection marker, or recombinantly combining the third DNA unit with an adjacent DNA unit from the second set to generate a second-type selectable vector comprising a fifth DNA unit, and obtaining a desired clone by selecting for the second selection marker.
• the invention provides a method for joining a series of DNA units to generate a DNA construct by (a) providing a first plurality of vectors, each comprising a DNA unit and a first selectable marker; (b) providing a second plurality of vectors, each comprising a DNA unit and a second selectable marker; (c) digesting a vector from (a) to produce a first fragment containing a DNA unit and at least one additional fragment not containing the DNA unit; (d) digesting a DNA from (b) to produce a second fragment containing a DNA unit and at least one additional fragment not containing the DNA unit, where only one of the first and second fragments contains an origin of replication; ligating the fragments to generate a product vector comprising a DNA unit from (c) ligated to a DNA unit from (d); selecting the product vector by selecting for either the first or second selectable marker; (e) digesting the product vector to produce a third fragment containing a DNA unit and at least one additional fragment not
• an open reading frame vector which has an internal type ⁇ 4-[7-*]-[*-8]-3 ⁇ , left-edge type ⁇ 4-[7-l]-[*-8]-3 ⁇ or right-edge type ⁇ 4-[7-*]-[6-8]-3 ⁇ architecture
• 7 and 8 are recognition sites for Type IIS or Type US-like restriction enzymes which cut to produce compatible overhangs "*"
• 1 and 6 are Type II restriction enzyme sites that are optionally present
• 3 and 4 are recognition sites for endonulceases (e.g., restriction enzymes) that are rare cutters (e.g., with 8-base pair or greater recognition sites).
• 1 is Nde I and/or 6 is Eco RI and/or 4 is Not I and/or 3 is Pac I.
• a method for identifying endonuclease (e.g., restriction) enzyme recognition sites useful for design of synthetic genes includes the steps of obtaining amino acid sequences for a plurality of functionally related polypeptide segments; reverse-translating the amino acid sequences to produce multiple polypeptide segment-encoding nucleic acid sequences for each polypeptide segment; and identifying endonuclease (e.g., restriction) enzyme recognition sites that are found in at least one polypeptide segment-encoding nucleic acid sequence of at least about 50% of the polypeptide segments.
• the functionally related polypeptide segments are polyketide synthase modules or domains, such as regions of high homology in PKS modules or domains.
• One or more parameters for positions of endonuclease (e.g., restriction) sites on a sequence of the synthetic gene are provided and occurrences of one or more selected endonuclease
• a set of overlapping oligonucleotide sequences which together comprise a sequence of the synthetic gene are generated.
• providing one or more parameters for positions of restriction sites on a sequence of the synthetic gene is followed by predicting all possible restriction sites that can be inserted in the randomized nucleotide sequence and optionally, identifying one or more unique restriction sites.
• sequence of the synthetic gene is divided into a series of synthons of selected length and then a set of overlapping oligonucleotide sequences is generated which together comprise a sequence of each synthon.
• one or more quality tests are performed on the set of overlapping oligonucleotide sequences, wherein the tests are selected from the group consisting of: translational errors, invalid restriction sites, incorrect positions of restriction sites, and aberrant priming.
• each oligonucleotide sequence is of a selected length and comprises an overlap of a predetermined length with adjacent oligonucletides of the set of oligonucleotides which together comprise the sequence of the synthetic gene.
• each oligonucleotide is about 40 nucleotides in length and comprises overlaps of between about 17 and 23 nucleotides with adjacent oligonucleotides.
• a set of overlapping oligonucleotide sequences are selected wherein each oligonucleotide anneals with its adjacent oligonucleotide within a selected temperature range.
• generating a set of overlapping oligonucleotide sequences includes providing an alignment cutoff value for sequence specificity, aligning each oligonucleotide sequence with the sequence of the synthetic gene and determining its alignment value, and identifying and rejecting oligonucleotides comprising alignment values lower than the alignment cutoff value.
• an order list of oligonucleotides which comprise a synthetic gene or a synthon is generated.
• removing of restriction sites includes identifying positions of preselected restriction sites in the randomized nucleotide sequence, identifying an ability of one or more codons comprising the nucleotide sequence of the restriction site for accepting a substitution in the nucleotide sequence of the restriction site wherein such substitution will (a) remove the restriction site and (b) create a codon encoding an amino acid identical to the codon whose sequence has been changed, and changing the sequence of the restriction site at the identified codon.
• inserting of restriction sites includes identifying selected positions for insertion of a selected restriction site in the randomized nucleotide sequence, performing a substitution in the nucleotide sequence at the selected position such that the selected restriction site sequence is created at the selected position, translating the substituted sequence to an amino acid sequence, and accepting a substitution wherein the translated amino acid sequence is identical to the reference amino acid sequence at the selected position and rejecting a substitution wherein the translated amino acid sequence is different from the reference amino acid sequence at the selected position.
• a translated amino acid sequence identical to the reference amino acid sequence comprises substitution of an amino acid with a similar amino acid at the selected position.
• the synthetic gene encodes a PKS module.
• the reference amino acid sequence is of a naturally occurring polypeptide segment.
• one or more steps of the method may performed by a programmed computer.
• a computer readable storage medium contains computer executable code for carrying out the method of the present invention.
• a sequence of a synthetic gene is provided, wherein the synthetic gene is divided into a plurality of synthons. Sequences of a plurality of synthon samples are also provided wherein each synthon of the plurality of synthons is cloned in a vector. And, a sequence of the vector without an insert is provided. Vector sequences from the sequence of the cloned synthon are eliminated and a contig map of sequences of the plurality of synthons is constructed. The contig map of sequences is aligned with the sequence of the synthetic gene; and a measure of alignment for each of the plurality of synthons is identified.
• errors in one or more synthon sequences are identified; and one or more informations are reported, the informations selected from the group consisting of: a ranking of synthon samples by degree of alignment, an error in the sequence of a synthon sample, and identity of a synthon that can be repaired.
• a system for high through-put synthesis of synthetic genes in accordance with the present invention includes a source microwell plate containing oligonucleotides for assembly PCR, a first source for amplification mixture including polymerase and buffers useable for assembly PCR, a second source for LIC extension primer mixture, and a PCR microwell plate for amplification of oligonucleotides.
• a liquid handling device retrieves a plurality of predetermined sets of oligonucleotides from the source microwell plate(s), combines the predetermined sets and the amplification mixture in wells of the PCR microwell plate, LIC extension primer mixture, and combines the LIC extension primer mixture and amplicons in a well of the PCR microwell plate.
• the system also includes a heat source for PCR amplification configured to accept the at least one PCR microwell plate.
• the invention provides a method for ligation of a plurality of DNA segments to obtain a ligation product that comprises sequences from each of the DNA segments in a predetermined order by (a) providing at least three DNA molecules, each comprising a DNA segment, wherein each segment is adjacent to one or two other segments in the ligation product, wherein each segment comprises a first region having sequence identity with a first adjacent DNA segment and a second region having sequence identity with a second adjacent DNA segment, if present; (b) cleaving each DNA molecule to produce a DNA segment with one or two ligatable ends, each ligatable end comprising at least a portion of the region having sequence identity with an adjacent DNA segment; wherein at least one segment comprises two ligatable ends after cleavage, (c) simultaneously ligating each segment to the adjacent segment or segments; and (d) selecting a ligation product comprising sequences from each of said DNA segments in a predetermined order.
• the invention provides a method for ligation of a plurality of DNA segments to obtain a ligation product that comprises sequences from each of the DNA segments in a predetermined order by (a) providing a Type 1 DNA molecule, a Type 2 DNA molecule and at least one Type 3 DNA molecule, each comprising a DNA segment that is adjacent to one or two other segments in the final ligation product, wherein (i) the Type 1 DNA molecule comprises a first DNA segment, and vector sequences comprising a first selectable marker, a first counter-selectable marker, a first cleavage site, and a second cleavage site, wherein cleavage of said second cleavage site produces a single-strand overhang in said first DNA segment which is ligatable to a single-strand overhang of an adjacent segment; (ii) the Type 2 DNA molecule comprises a second DNA segment, and vector sequences comprising a second selectable marker, a second counter-selectable marker, a
• a variation of this method includes transforming cells with ligation products produced in step (c); and (e) selecting transformants that express said first and second selectable markers and do not express said first, second, or third a counter- selectable marker.
• Another variation of this method includes (f) isolating the ligation product comprising sequences from each of said DNA segments in a predetermined order from the transformants or their progeny.
• the DNA molecules cleaved in step (b) are cleaved in the same container.
• the first and second selectable markers are genes conferring drug resistance and/or the first, second and third counter-selectable markers are selected from the group consisting of ccdB (anti-DNA gyrase protein), sacB (sucrose sensitivity), araB (ribulose sensitivity), tet-4R (tetracycline resistance/fusaric acid hypersensitivity).
• ccdB anti-DNA gyrase protein
• sacB sacB
• araB ribulose sensitivity
• tet-4R tetracycline resistance/fusaric acid hypersensitivity
• the first and third cleavage sites are the same; the second and fourth cleavage sites are the same; and/or the 5-prime cleavage site of at least one Type 3 DNA molecule is the same as the 3-prime cleavage site of the same Type 3 DNA molecule.
• the first and third cleavage sites are sites cleaved by a Type IIS or Type US-like restriction enzyme; and/or the second and fourth cleavage sites are sites cleaved by a Type IIS or Type US-like restriction enzyme; and/or said 5-prime and 3- prime cleavage sites of at least one Type 3 DNA molecule are sites cleaved by a Type IIS or Type US-like restriction enzyme.
• the first, second, third, fourth, 5-prime and 3-prime cleavage sites are sites cleaved by a Type IIS or Type US-like restriction enzyme.
• the first, second, third, fourth, 5-prime and 3-prime cleavage sites are sites cleaved by the same Type IIS or Type US-like restriction enzyme.
• the DNA segments of the Type 1, Type 2 and Type 3 DNA molecules comprise encoding sequences of a polypeptide segment of a polyketide synthase.
• the DNA segments of the Type 1, Type 2 and Type 3 DNA molecules comprise encoding sequences encoding a polyketide synthase.
• the invention provides a composition of (i) a Type 1 DNA molecule, DNA molecule having comprising a first DNA segment, a first selectable marker, a first counter-selectable marker, a first cleavage site, and a second cleavage site; wherein cleavage of the second cleavage site produces a single-strand overhang in the first segment which is ligatable to a single-strand overhang of an adjacent segment; (ii) a Type 2 DNA molecule having a second DNA segment, a second selectable marker, a second counter- selectable marker, a third cleavage site, and a fourth cleavage site wherein cleavage of the fourth cleavage site produces a single-strand overhang in the first segment which is ligatable to a single-strand overhang of an adjacent segment; (iii) at least one Type 3 DNA molecule having a DNA segment, a third counter-selectable marker, a 5-prime cleavage site
• the composition contains at least two Type 3 DNA molecules.
• the composition contains an endonuclease that cleaves at the first, second, third, or fourth cleavage sites or at one or more 5-prime or 3-prime cleavage sites, or an endonuclease that cleaves at the first, second, third, and fourth cleavage sites and at one or more 5-prime or 3- prime cleavage sites.
• the composition contains at least two Type 3 DNA molecules comprising 5-prime or 3-prime cleavage sites and wherein the endonuclease that cleaves at the third and fourth cleavage sites and at the 5-prime and 3-prime cleavage sites of said Type 3 DNA molecules.
• the invention provides a composition containing the products resulting from cleavage of the Type 1, Type 2 and Type 3 DNAs of Claim 14 at the first, second, third, fourth, 5-prime and 3-prime cleavage sites.
• the composition of Claim 19 additionally containing DNA ligase.
• the invention provides a cloning vector having, in the order shown, (a)SIS - CSM- R - USM or SIS - USM - R - CSM; or (b) SIS-CSM-SM, where SIS is a synthon insertion site, CSM is a counter-selectable marker; SM and USM are selectable markers, and R is an endonuclease cleavage site.
• the SIS comprises - N R 2 -N 2 - where Ni and N 2 are recognition sites for nicking enzymes, and may be the same or different, and R 2 is a recognition site for an endonuclease.
• SM and USM are genes conferring drug resistance.
• the invention provides, a composition comprising each of: (a) a vector of the formula R, - Sy - 2S ⁇ - CSM- R 2 -USM; (b) a vector of the formula 2S 2 - Sy - R 3 - USM - Ri - CSM; and (c) a vector of the formula 2S 3 - Sy - 2S 4 - CSM - SM; where 2Sj, 2S 2 , 2S 3 and 2S 4 are recognition sites for Type IIS or Type US-like restriction enzymes, which may be the same or different, each Sy is a different synthon coding region, Ri and R 3 are endonuclease cleavage sites and are the same or are different, R 2 and R 4 are endonuclease cleavage sites that, upon cleavage, result in compatible ends, 2Sj, 2S 2 , 2S 3 , and 2S 4 are endonuclease cleavage sites and are the
• R] and R 3 are different.
• the composition also contains an endonuclease that cleaves at one ormore of R ⁇ ,R 2 , R 3 , R 4 , 2S ⁇ , 2S 2 , 2S 3 , and 2S 4.
• the composition contains 2, 3, 4, 5, or 6 vectors of the formula 2S 3 - Sy - 2S 4 - CSM - SM, each with a different Sy.
• FIGURE 1 shows a UDG-cloning cassette ("cloning linker") and a scheme of vector preparation for ligation-independent cloning (LIC) using the nicking endonuclease N. BbvC IA.
• FIGURE 1 A UDG-cloning cassette. Sac I and nicking enzyme sites used in vector preparation are labeled.
• FIGURE IB Scheme of vector preparation for LIC using nicking endonuclease N. BbvC IA.
• FIGURE 3A shows the Method S joining method using Vector Pair I.
• FIGURE 3B shows the Method S joining using Vector Pair II.
• 2S ⁇ - 4 are recognition sites for Type IIS restriction enzymes, and A, B, B and C, respectively, are the cleavage sites for the enzymes.
• FIGURE 4 shows a vector pair useful for stitching.
• FIGURE 4A Vector pKos293-172-2.
• FIGURE 4B Vector pKos293-172-A76.
• Both vectors contain a UDG- cloning cassette with N.Bbv C IA recognition sites, a "right restriction site” common to both vectors (Xho I site), a "left restriction site” different for each vector (e.g., Eco RV or Sru I site), a first selection marker common to both vectors (carbenicillin resistance marker) and second selection markers that are different in each vector (chloramphenicol resistance marker or kanamycin resistance marker).
• FIGURE 7 shows a non-pairwise selection strategy for stitching of synthons 1-9 to make module 1-2-3-4-5-6-7-8-9.
• the synthons are joined at the following cohesive ends: 1-2 NgoM
• FIGURE 9 is a flowchart showing a GeMS algorithm.
• FIGURE 10A is a flowchart showing generation of codon preference table for a synthetic gene
• FIGURE 10B is a flowchart showing an algorithm for generating a randomized and codon optimized gene sequence.
• FIGURE 11 is a flowchart showing a restriction site removal algorithm.
• FIGURE 13 is a flowchart showing an algorithm for oligonucleotide design.
• FIGURE 14 is a flowchart showing an algorithm for rapid analysis of synthon
• FIGURE 15 shows a PAGE analysis of DEBS. Soluble protein extracts from synthetic (sMod2) and natural sequence (nMod2) Mod2 strains were sampled 42 h after induction and analyzed by 3-8% SDS-PAGE. Positions of MW standards are indicated at the right. The gel was stained with Sypro Red (Molecular Probes).
• FIGURE 17 shows the stitching and selection strategy for construction of synthetic DEBS genes.
• A synthon cloning vector 293-172-A76;
• B synthon cloning vector 293-172-2.
• FIGURE 18 shows restriction sites and synthons used in construction of a synthetic Epothilone PKS gene.
• FIGURE 19 shows an automated system for high throughput gene synthesis and analysis.
• FIGURE 20A-D illustrates stitching using "Method M.”
• DETAILED DESCRIPTION [0078] The outline below is provided to assist the reader. The organization of the disclosure below is for convenience, and disclosure of an aspect of the invention in a particular section, does not imply that the aspect is not related to disclosure in other, differently labeled, sections. 1. DEFINITIONS
• a “protein” or “polypeptide” is a polymer of amino acids of any length, but usually comprising at least about 50 residues.
• polypeptide segment can be used to refer a polypeptide sequence of interest.
• a polypeptide segment can correspond to a naturally occurring polypeptide (e.g., the product of the DEBS ORF 1 gene), to a fragment or region of a naturally occurring polypeptide (e.g., a DEBS module 1, the KS domain of DEBS module 1 , linkers, functionally defined regions, and arbitrarily defined regions not corresponding to any particular function or structure), or a synthetic polypeptide not necessarily corresponding to a naturally occurring polypeptide or region.
• a naturally occurring polypeptide e.g., the product of the DEBS ORF 1 gene
• a fragment or region of a naturally occurring polypeptide e.g., a DEBS module 1, the KS domain of DEBS module 1 , linkers, functionally defined regions, and arbitrarily defined regions not corresponding to any particular function or structure
• synthetic polypeptide not necessarily corresponding to a naturally occurring polypeptide or region.
• polypeptide segment-encoding sequence can be the portion of a nucleotide sequence (either in isolated form or contained within a longer nucleotide sequence) that encodes a polypeptide segment (for example, a nucleotide sequence encoding a DEBS1 KS domain); the polypeptide segment can be contained in a larger polypeptide or an entire polypeptide.
• polypeptide segment- encoding sequence is intended to encompass any polypeptide-encoding nucleotide sequence that can be made using the methods of the present invention.
• the terms "synthon” and "DNA unit” refer to a double-stranded polynucleotide that is combined with other double-stranded polynucleotides to produce a larger macromolecule (e.g., a PKS module-encoding polynucleotide).
• Synthons are not limited to polynucleotides synthesized by any particular method (e.g., assembly PCR), and can encompass synthetic, recombinant, cloned, and naturally occurring DNAs of all types. In some cases, three different regions of a synthon can be distinguished (a coding region and two flanking regions).
• the portion of the synthon that is incorporated into the final DNA product of synthon stitching (e.g., a module gene) can be referred to as the "synthon coding region.”
• the regions of the synthon that flank the synthon coding region, and which do not become part of the product DNA can be referred to as the “synthon flanking regions.”
• the synthon flanking regions are physically separated from the synthon coding region during stitching by cleavage using endonucleases such as restriction enzymes.
• multisynthon refers to a polynucleotide formed by the combination (e.g., ligation) of two or more synthons (usually four or more synthons).
• a “multisynthon” can also be referred to as a “synthon” (see definition above).
• a “module” is functional unit of a polypeptide.
• PKS module refers to a naturally occurring, artificial or hybrid PKS extension module.
• PKS extension modules comprise KS and ACP domains (usually one KS and one ACP per module), often comprise an AT domain (usually one AT domain and sometimes two AT domains) where the AT activity is not supplied in trans or from an adjacent module, and sometimes comprising one or more of KR, DH, ER, MT (methytransferase), A (adenylation), or other domains.
• module can refer to the set of domains and interdomain linking regions extending approximately from the carboxy terminus of one ACP domain to the carboxy terminus of the next ACP domain (e.g., including a sequence linking the modules, corresponding to the Spe I-Mfe I region of the module shown in Figure 6) linker or, alternatively can refer to the set not including the linker sequence (e.g., corresponding roughly to the Mfe I-Xba I region of the module shown in Figure 6).
• linker e.g., corresponding roughly to the Mfe I-Xba I region of the module shown in Figure 6.
• multimodule refers to a single polypeptide comprising two or more modules.
• PKS accessory unit refers to regions or domains of PKS polypeptides (or which function in polyketide synthesis) other than extension modules or domains of extension modules.
• PKS accessory units include loading modules, interpolypeptide linkers, and releasing domains.
• PKS accessory units are known in the art. The sequences for PKS loading domains are publicly available (see, e.g., Table 12). Generally, the loading module is responsible for binding the first building block used to synthesize the polyketide and transferring it to the first extension module.
• AKL thioesterase domain
• TE thioesterase domain
• amino acid-incorporating activities such as those encoded by the rapP gene from the rapamycin cluster and its homologs from FK506, FK520, and the like; the amide-forming activities such as those found in the rifamycin and geldanamycin PKS; and hydrolases or linear ester-forming enzymes.
• a "gene” is a DNA sequence that encodes a polypeptide or polypeptide segment.
• a gene may also comprise additional sequences, such as for transcription regulatory elements, introns, 3 '-untranslated regions, and the like.
• a "synthetic gene” is a gene comprising a polypeptide segment- encoding sequence not found in nature, where the polypeptide segment-encoding sequence encodes a polypeptide or fragment or domain at least about 30, usually at least about 40, and often at least about 50 amino acid residues in length.
• module gene or “module-encoding gene” refers to a gene encoding a module; a “PKS module gene” refers to a gene encoding PKS module.
• multimodule gene refers to a gene encoding a multimodule.
• a "naturally occurring" PKS, PKS module, PKS domain, and the like is a PKS, module, or domain having the amino acid sequence of a PKS found in nature.
• a "naturally occurring" PKS gene, PKS module gene, or PKS domain gene is a gene having the nucleotide sequence of a PKS gene found in nature.
• a "gene library” means a collection of individually accessible polynucleotides of interest.
• the polynucleotides can be maintained in vectors (e.g., plasmid or phage), cells (e.g., bacterial cells), as purified DNA, or in other forms.
• Library members can be stored in a variety of ways for retrieval and use, including for example, in multiwell culture or microtiter plates, in vials, in a suitable cellular environment (e.g., E.
• coli cells as purified DNA compositions on suitable storage media (e.g., the Storage IsoCode® IDTM DNA library card; Schleicher & Schuell BioScience), or a variety of other art-known library forms.
• suitable storage media e.g., the Storage IsoCode® IDTM DNA library card; Schleicher & Schuell BioScience
• a library has at least about 10 members, more often at least about 100, preferably at least about 500, and even more preferably at least about 1000 members.
• “individually accessible” is meant that the location of the selected library member is known such that the member can be retrieved from the library.
• polypeptides corresponds to a naturally occurring polypeptide when it has substantially the same amino acid sequence.
• a KS domain encoded by a synthetic gene would correspond to the KS domain of module 1 of D ⁇ BS if the KS domain encoded by a synthetic gene has substantially the same amino acid sequence as the KS domain of module 1 of D ⁇ BS.
• adjacent when referring to adjacent DNA units such as adjacent synthons, refers to sequences that are contiguous (or overlapping) in a naturally occurring or synthetic gene. In the case of “adjacent synthons,” the sequences of the synthon coding regions are contiguous or overlapping in the synthetic gene encoded in the synthons.
• edge in the context of a polynucleotide or a polypeptide segment, refers to the region at the terminus of a polynucleotide or a polypeptide (i.e., physical edge) or near a boundary delimiting a region of the polypeptide (e.g., domain) or polynucleotide (e.g., domain-encoding sequence).
• a sequence motif or endonuclease (e.g., restriction enzyme) site is “near” the nucleotide sequence encoding an amino-or carboxy-terminus of a PKS domain in a module when the motif or site is closer to the specified terminus (boundary) than to the terminus (boundary) of any other domain in the module.
• a sequence motif or endonuclease (e.g., restriction enzyme) recognition or cleavage site is "near" the nucleotide sequence encoding an amino-or carboxy-terminus of a PKS module when the motif or site is closer to the specified terminus (boundary) than to the terminus of any domain in the module.
• PKS domains can be determined by methods known in the art by aligning the sequence of a subject domain with the sequences of other PKS domains of a similar type (e.g., KS, ER, etc.) and identifying boundaries between regions of relatively high and relatively low sequence identity. See Donadio and Katz, 1992, "Organization of the enzymatic domains in the multifunctional polyketide synthase involved in erythromycin formation in Saccharopolyspora erythraea" Gene 111 :51-60. Programs such as BLAST, CLUSTALW and those available at http://www.nii.res.in/pksdb.html can be used for alignment.
• a motif or endonuclease (e.g., restriction enzyme) site that is near a boundary is not more than about 20 amino acid residues from the boundary.
• a "sequence-specific nicking endonuclease” or “sequence-specific nicking enzyme” is an enzyme that recognizes a double-stranded DNA sequence, and cleaves only one strand of DNA.
• Exemplary nicking endonucleases are described in U.S. Patent Application 20030100094 Al "Method for engineering strand-specific, sequence-specific, DNA-nicking enzymes.”
• Exemplary nicking enzymes include N.Bbv C IA, N.BstNB I and N.Alw I (New England Biolabs).
• endonucleases are so-called homing endonucleases, of which I-Ceu I R0699, 1-Sce I R0694, PI-Psp I R0695, Pl-Sce I R0696 and others are currently available (New England Biolabs) (see generally Belfort et al., 1997, Nucleic Acids Res. 25:3379-88; Dujon et al., 1989, Gene 82:115-118; Perler et al., 1994, Nucleic Acids Res. 22:1125-27; Jasin, 1996, Trends in Genetics 12:224-228; Gimble et al., 1996, J. Mol. Biol.
• the endonuclease used is a homing endonuclease and/or the recognition site (e.g., a site in a vector) is a sequence recognized by a homing endonuclease.
• a "restriction site" in a vector that comprises can equivalently be, in some embodiments, any sequence specific endonuclease (e.g., homing endonuclease) recognition site; a process that comprises cleavage at a "restriction site” can equivalently include cleavage by any sequence specific endonuclease; and use of a "restriction enzyme” can equivalently include use of any sequence specific endonuclease.
• an endonuclease cleavage site may be within or outside of the endonuclease recognition site.
• a "TypellS” restriction endonuclease is a subset of type IIA in which at least one cleavage site is outside the recognition site.
• Type IIS restriction enzymes
• reference to "Type IIS” restriction enzymes refers to those Type IIS enzymes for which both DNA strands are cut outside the recognition site and on the same side of the restriction site.
• Type IIS enzymes are selected that produce an overhang of 2 to 4 bases.
• Other endonucleases that cleave outside a recognition site include those sometimes referred to as Type IN restriction enzymes.
• Type IN enzymes are large, combination restriction-and- modification enzymes. These enzymes cleave outside of their recognition sequences; those that recognize continuous sequences (e.g., Eco57 I: CTGAAG) cleave on just one side; those that recognize discontinuous sequences (e.g., Beg I: [5' ... ⁇ 10( ⁇ ) C G A (N)6 T G C (N)12 ⁇ ... Y 1 3' ... ⁇ 12(N) G C T (N)6 A C G (N)10 ⁇ ... 5'] ) and cleave on both sides releasing a small fragment containing the recognition sequence.
• Another type of enzyme that cleaves outside a recognition sequence is a so-called Type III enzyme.
• TypellS endonucleases and others that cleave outside the recognition site can be referred to as "Type US- like" endonucleases.
• this patent sometimes refers to a "Type IIS” restriction enzyme.
• any reference herein, unless otherwise indicated by context, to use of a Type IIS endonuclease, a Type IIS restriction site, a Type IIS cleavage site and the like is intended to also encompass and refer to use of other Type US-like endonucleases, in at least some embodiments of the invention, so long as they can accomplish the equivalent purpose.
• Exemplary restriction endonucleases include, without limitation, Aat II, Acl I, Afe I, Afl II, Age I, Ahd I, Alw 261, Alw ⁇ I, Apa I, Apa LI, Asc I, Ase I, Avr II, Bam HI, Bbs I, Bbv CI, Bci NI, Bel I, Bfu Al, Bgl I, Bgl II, Blp I, Bpl I, Bpm I, Bpu 101, Bsa I, Bsa Bl, Bsa MI, Bse RI, Bsg I, Bsi WI, Bsm Bl, Bsm I, Bsp El, Bsp HI, Bsr Bl, Bsr DI, Bsr GI, Bss HII, Bss SI, Bst API, Bst Bl, Bst EII, Bst XI, Bsu 361, Cla I, Dra I, Dra III, Drd
• ligatable ends refers to ends of two DNA fragments (or ends of the same molecule) that can be ligated.
• “Ligatable ends” include blunt ends and “cohesive ends” (having single-stranded overhangs).
• Two cohesive ends are “compatible” when they can anneal and be ligated (e.g., when each overhang is of the 3'-hydroxyl end; each is of the same length, e.g., 4 nucleotide units, and the sequences of the two overhangs are reverse complements of each other).
• a “restriction site” or endonuclease site refers to a recognition site that is at least 5, and usually at least 6 base pairs in length.
• the endonuclease site is recognized by a "rare cutter” and has a recognition site of at least 7, at least 8, at least 9 or at least 10 base pairs in length.
• the endonuclease cleavage site may or may not be located in the recognition site.
• a "useful endonuclease site” refers to a site that is either unique or, if not unique, exists in a pattern and number in a specified polynucleotide or specified region of a polynucleotide such that digestion at all the of the sites in a specified polynucleotide (e.g., vector) or specified region of a polynucleotide (e.g., module gene) would achieve essentially the same result as if the site was unique.
• a specified polynucleotide e.g., vector
• specified region of a polynucleotide e.g., module gene
• vector refers to polynucleotide elements that are used to introduce recombinant nucleic acid into cells for either expression or replication and which have an origin of replication and appropriate transcriptional and/or translational control sequences, such as enhancers and promoters, and other elements for vector maintenance.
• vectors are self-replicating circular extrachromosomal DNAs. Selection and use of such vehicles is routine in the art.
• An "expression vector” includes vectors capable of expressing a DNA inserted into the vector (e.g., a DNA sequence operatively linked with regulatory sequences, such as promoter regions).
• an expression vector refers to a recombinant DNA or RNA construct, such as a plasmid, a phage, recombinant virus or other vector that, upon introduction into an appropriate host cell, results in expression of the cloned DNA.
• selectable marker and “counter-selectable marker” refer to genes whose expression allows selection of cells that have been transformed or transfected with a vector containing the gene.
• a “selectable marker” is a gene that, when expressed in a cell grown under specified selection conditions that are lethal or growth-inhibiting for similar cells not expressing the gene, allow the cell expressing the marker to survive and proliferate.
• a selectable marker can encode resistance for a substance that would normally kill the organism.
• selectable markers and selection methods are known in the art and can be used for selection.
• the marker is a gene for drug resistance such as carb (carbenicillin resistance [e.g., bla]), tet (tetracycline resistance), kan (kanamycin resistance [e.g., aph(3')- II]), strep (streptomycin resistance) or cm (chloramphenicol resistance [e.g., cat]).
• a "counter-selectable marker” is a gene that, when expressed in a cell grown under specified selection conditions, results in cell death (thereby selecting against any cell containing the gene).
• a wide variety of counter-selectable markers and selection methods are known in the art and can be used for selection. Examples include ccdB (anti-DNA gyrase protein), sacB (sucrose sensitivity), araB (ribulose sensitivity), and tet-4R (tetracycline resistance/fusaric acid hypersensitivity).
• a specified amino acid is "similar" to a reference amino acid in a protein when substitution of the specified amino acid for the reference amino does not substantially modify the function (e.g., biological activity) of the protein.
• Amino acids that are similar are often conservative substitutions for each other.
• the following six groups contain amino acids that are conservative substitutions for one another: [alanine; serine; threonine]; [aspartic acid, glutamic acid], [asparagine, glutamine], [arginine, lysine], [isoleucine, leucine, methionine, valine], and [phenylalanine, tyrosine, and tryptophan]. Also see Creighton, 1984, PROTEINS, W.H. Freeman and Company.
• a nonribosomal peptide synthase is an enzyme that produces a peptide product by joining individual amino acids through a ribosome-independent process.
• NRPS include gramicidin synthetase, cyclosporin synthetase, surfactin synthetase, and others.
• module and domain generally refers to polypeptides or regions of polypeptides, while the terms “module gene” and “domain gene,” or grammatical equivalents, refer to a DNA encoding the protein. Any inadvertent deviations from this convention will be apparent from context. For example, it will be clear that “restriction sites at module edges” refers to restriction sites in the region of the module gene encoding the edge of the module polypeptide sequence.
• the present invention relates to strategies, methods, vectors, reagents, and systems for synthesis of genes, production of libraries of such genes, and manipulation and characterization of the genes and corresponding encoded polypeptides.
• the invention provides new methods and tools for synthesis of genes encoding large polypeptides. Examples of genes that may be synthesized include those encoding domains, modules or polypeptides of a polyketide synthase (PKS), genes encoding domains, modules or polypeptides of a non-ribosomal peptide synthase (NRPS), hybrids containing elements of both PKSs and NRPSs, viral genomes, and others.
• PKS polyketide synthase
• NRPS non-ribosomal peptide synthase
• the methods of the invention for producing synthetic genes encoding polypeptides of interest can include the following steps: a) Designing a gene that encodes a polypeptide segment of interest; b) Designing component oligonucleotides for synthesis of the gene; c) Synthesizing the polypeptide-segment encoding gene by: i) making synthons encoding portions of the gene; and, ii) "stitching" synthons together to produce multisynthons (i.e., larger DNA units) that encode the polypeptide segment of interest.
• multisynthons i.e., larger DNA units
• the invention relates to a universal design of genes encoding PKS modules (or other polypeptides) in which useful restriction sites flank functionally defined coding regions (e.g., sequence encoding modules, domains, linker regions, or combinations of these).
• the design allows numerous different modules to be cloned into a common set of vectors for manipulation (e.g., by substitution of domains) and/or expression of diverse multi-modular proteins.
• the invention provides large libraries of PKS module-encoding genes.
• the invention provides vectors and methods useful for gene synthesis.
• the invention provides algorithms useful for design of synthetic genes. [0119] In a related aspect, the invention provides automated systems useful for gene synthesis.
• the invention provides a method for making a synthetic gene encoding a PKS module by producing a plurality of DNA units by assembly PCR or other method (where each DNA unit encodes a portion of the PKS module) and combining the DNA units in a predetermined sequence to produce a PKS module-encoding gene.
• the method includes combining the module-encoding gene in-frame with a nucleotide sequence encoding a PKS extension module, a PKS loading module, a thioesterase domain, or an PKS interpolypeptide linker, thereby producing a PKS open reading frame.
• the methods of the invention for synthesis of genes encoding PKS modules can include any one or more the following steps: a) Designing a PKS module (e.g., for production of a specific polyketide, or for inclusion in a library of modules); b) Designing a synthetic gene encoding the desired PKS module; c) Designing component oligonucleotides for synthesis of the gene; d) Synthesizing the module gene by: i) making synthons encoding portions of the module gene; and, ii) "stitching" synthons together; e) modifying module genes; and/or making open reading frames comprising module gene(s) and/or accessory unit gene(s); and/or producing libraries of module-encoding genes; f) expressing a module gene from (d) or (e) in a host cell, optionally in combination with other polypeptides.
• a PKS module e.g., for production of a specific polyketide, or for inclusion in a library of
• the nucleotide sequence of a synthetic gene of the invention will vary depending on the nature and intended uses of the gene. In general, the design of the genes will reflect the amino acid sequence of the polypeptide or fragment (e.g., PKS module or domain) to be encoded by the gene, and all or some of: a) the codon preference of intended expression host(s). b) the presence (introduction) of useful restriction sites in specified locations of the synthetic gene, c) the absence (removal) of undesired restriction sites in the gene or in specified regions of the gene, d) compatibility with synthetic methods disclosed herein, especially high- throughput methods.
• the design of the genes will reflect the amino acid sequence of the polypeptide or fragment (e.g., PKS module or domain) to be encoded by the gene, and all or some of: a) the codon preference of intended expression host(s). b) the presence (introduction) of useful restriction sites in specified locations of the synthetic gene, c) the absence (removal) of undesi
• a variety of criteria are available to the practitioner for selecting the gene(s) to be synthesized by the methods of the invention.
• the chief consideration is usually the protein encoded by the gene.
• a gene can be synthesized that encodes a protein at least a portion of which has a sequence the same or substantially the same as a naturally occurring domain, module, linker, or other polypeptide unit, or combinations of the foregoing.
• numerous nucleic acid sequences that encode the protein can be determined by reverse-translating the amino acid sequence. Methods for reverse translation are well known.
• reverse translation can be carried out in a fashion that "randomizes" the codon usage and optionally reflects a selected codon preference or bias. Since the synthetic genes of the invention may be expressed in a variety of hosts consideration of the codon preferences of the intended expression host may be have benefits for the efficiency of expression.
• nucleotide acid sequence of the synthetic gene may be designed to avoid clusters of adjacent rare codons, or regions of sequence duplication.
• suitable expression hosts will depend on the protein encoded. For PKS proteins, suitable hosts include cells that natively produce modular polyketides or have been engineered so as to be capable of producing modular polyketides.
• Hosts include, but are not limited to, actinomycetes such as Streptomyces coelicolor, Streptomyces venezuelae, Streptomyces fradiae, Streptomyces ambofaciens, and Saccharopolyspora erythraea, eubacteria such as Escherichia coli, myxobacteria such as Myxococcus xanthus, and yeasts such as Saccharomyces cerevisiae.
• actinomycetes such as Streptomyces coelicolor, Streptomyces venezuelae, Streptomyces fradiae, Streptomyces ambofaciens, and Saccharopolyspora erythraea
• eubacteria such as Escherichia coli
• myxobacteria such as Myxococcus xanthus
• yeasts such as Saccharomyces cerevisia
• the DNA sequence of a naturally occurring gene encoding the protein is used to design the synthetic gene.
• the naturally occurring DNA sequence is modified as described below (e.g., to remove and introduce restriction sites) to provide the sequence of the synthetic gene.
• the design of synthetic genes of the invention may also involve the inclusion of desired endonuclease (e.g., restriction) sites at certain locations in the gene and/or exclusion of undesired endonuclease (e.g., restriction) sites in the gene or in specified regions of the gene, as well as compatibility with synthetic methods used to make the gene(s).
• desired endonuclease e.g., restriction
• undesired endonuclease e.g., restriction
• an "undesired" restriction site e.g., Eco RI site
• synthetic PKS module genes are produced by combining synthons ranging in length from about 300 to about 700 bp, more often from about 400 to about 600 bp, and usually about 500 bp.
• PKS modules naturally occurring PKS module genes (and corresponding synthetic genes) are in the neighborhood of about 5000 bp in length. Allowing for some overlap between sequences of adjacent synthons, ten to twelve 500-bp synthons are typically combined to produce a 5000 bp module gene encoding a naturally occurring module or variant thereof.
• the number of synthons that are "stitched" together can be at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, or at least 10, or can be a range delimited by a first integer selected from 2, 3, 4, 5, 6, 7, 8, 9, or 10 and a second selected from 5, 10, 20, 30 or 50 (where the second integer is greater than the first integer).
• the next section describes synthon production.
• the following section, ⁇ 4.2 describes the synthesis of module genes by stitching synthons, as well as vectors useful for stitching.
• Synthons can be produced in a variety of ways. Just as module genes are produced by combining several synthons, synthons are generally produced by combining several shorter polynucleotides (i.e. oligonucleotides). Generally synthons are produced using assembly PCR methods.
• Useful assembly PCR strategies are known and involve PCR amplification of a set of overlapping single-stranded polynucleotides to produce a longer double-stranded polynucleotide (see e.g., Stemmer et al., 1995, "Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides” Gene 164:49-53; Withers-Martinez et al., 1999, "PCR-based gene synthesis as an efficient approach for expression of the A+T-rich malaria genome” Protein Eng.
• synthons can be prepared by other methods, such as ligase-based methods (e.g., Chalmer and Curnow, 2001, “Scaling Up the Ligase Chain Reaction-Based Approach to Gene Synthesis” Biotechniques 30:249-252). [0135] It will become apparent to the reader that the sequences of the oligonucleotide components of a synthon determine the sequence of the synthon, and ultimately the synthetic gene generated using the synthon.
• sequences of the oligonucleotide components (1) encode the desired amino acid sequence, (2) usually reflect the codon preferences for the expression host, (3) contain endonuclease (e.g., restriction) sites used during synthesis of, or desired in, the synthetic gene, (4) are designed to exclude from the synthetic gene endonuclease (e.g., restriction) sites that are not desired, (5) have annealing, priming and other characteristics consistent with the synthetic method (e.g. assembly PCR), and (6) reflect other design considerations described herein.
• endonuclease e.g., restriction
• Synthons about 500 bp in length are conveniently prepared by assembly amplification of about twenty-five 40-base oligonucleotides ("40-mers").
• uracil-containing oligonucleotides are added to the ends of synthons (i.e., synthon flanking regions) to facilitate ligation independent cloning (see, e.g., Example 1).
• the oligonucleotides themselves are designed according to the principles described herein, can be prepared using by conventional methods (e.g., phosphoramidite synthesis) and/or can be obtained from a number of commercial sources (e.g., Sigma- Genosys, Operon).
• oligonucleotide preparation usually is desalted but not gel purified (see, e.g., Example 1). Assembly and amplification conditions are selected to minimize introduction of mutations (sequence errors).
• stitching can be used to combine two or more PKS module genes to prepare multimodule genes or to combine any of a variety of other combinations of polynucleotides (e.g., a promoter sequence and a RNA encoding sequence).
• Stitching involves joining adjacent DNA units (e.g., synthons) by a process in which a first DNA unit (e.g., a first synthon or multisynthon) in a first vector is combined with an adjacent DNA unit (e.g., an adjacent synthon or multisynthon) in a second vector that is differently selectable from the first vector.
• a first DNA unit e.g., a first synthon or multisynthon
• an adjacent DNA unit e.g., an adjacent synthon or multisynthon
• Each of the two vectors contains an origin of replication (as used herein, reference to a “vector” indicates the presence of an origin of replication).
• the two vectors containing the adjacent DNA units (hereinafter, “synthons") are sometimes referred to as a “cognate pair” or as the "donor” and "acceptor” vectors.
• each of the two vectors is digested with endonucleases (e.g., restriction enzymes) to generate fragments with compatible (usually cohesive) ligatable ends in the synthon sequences (allowing the synthons to be joined by ligation) and to generate compatible (usually cohesive) ligatable ends outside the synthon sequences such that the two synthon-containing vector fragments can be ligated to generate a new, selectable, vector containing the joined synthon sequences (multisynthon).
• endonucleases e.g., restriction enzymes
• the selectable marker of step (d) is not the same as the selectable marker of the preceding stitching step and/or is not the same as the selectable marker of the subsequent stitching step; lao, ldo, la n , ld n are the same and/or Lao, Ldo, La n , and Ld n are created by a Type IIS restriction enzyme; the synthons SAo, SD 0 , SAn + ioo, and SDn+ioo are synthetic DNAs; any one or more of synthons SAo, SDo, SAn+ioo, or SDn+ioo is a multisynthon; and/or the multisynthon product of step (e) encodes a polypeptide comprising a PKS domain.
• the first stitching approach referred to as “Method S”
• the second stitching approach is facilitated by recognition sites for endonucleases that cleave within the recognition site (e.g., conventional Type II restriction enzymes).
• Method M The third stitching approach, referred to as “Method M,” is particularly useful for ligation of multiple DNA fragments without the requirement of intervening purification of ligation products.
• the stitching approaches described here differ in the joining step, but use similar methods for cloning into assembly vectors and selection. Each of these steps is discussed below.
• LIC ligation-independent cloning
• One LIC method involves creating single-strand complementary overhangs sufficiently long for annealing to each other (often 12 to 20 bases) on (a) the synthon and (b) the vector.
• a host e.g., E. coli
• a closed, circular plasmid is generated with high efficiency.
• 3 Aoverhangs, or "LIC extensions” are introduced to the synthon using PCR primers that are later partially destroyed. This can be accomplished by incorporating uracil (U) residues (instead of thymidine) into a PCR primer, linking the primer onto the 3' ends of the product of assembly PCR described above, and digesting with Uracil- DNA Glycosidase (UDG). UDG cleaves the uracil residues from the sugar backbone, leaving the bases of the other strand free to interact with the complementary strand on the vector (see, e.g., Rashtchian et al., 1992).
• U uracil residues
• Example 2 The nicked, linearized, DNA is treated with exonuclease III to remove the small oligonucleotides (exonuclease III cleaves 3'-->5', providing there are no 3'- overhangs).
• exonuclease III cleaves 3'-->5', providing there are no 3'- overhangs.
• the 3 Aoverhang on the vector is generated by the action of endonuclease VIII (see Example 2).
• the "central" restriction site is positioned such that cleavage with the restriction endonuclease and nicking endonuclease(s), followed by digestion with the exo- or endo-nuclease results in 3' overhangs suitable for annealing to a fragment with complementary 3' overhangs.
• clones with a small number of errors can be corrected using site-directed mutagenesis (SDM).
• SDM site-directed mutagenesis
• One method for SDM is PCR-based site-directed mutagenesis using the 40-mer oligonucleotides used in the original gene synthesis.
• the sequence that is the same in the two synthons usually comprises at least 3 base pairs, and often comprises at least 4 base pairs. In an embodiment, the sequence is 5'-GATC-3'.
• Table 2 shows exemplary Type IIS restriction enzymes and recognition sites. Figure 2 illustrates the Method S joining method using Bbs I and Bsa I as enzymes. It will be understood that the method can be carried out using other types of endonucleases that cleave outside the recognition site at defined positions relative to the recognition sequence to produce a ligatable end.
• restriction sites e.g., Ri, R , L, L'
• endonucleases e.g., homing endonucleases
• the stitching vectors have i) a synthon insertion site (SIS); ii) a "right" restriction site (Rj) common to both vectors or, alternatively, that is different in each vector but which produce compatible ends; iii) a first selection marker (SM2 or SM3) that is different in each vector; iv) a second selection marker (SM4 or SM5) that is different in each vector; and, v) optionally a third selection marker (SMI) common to both vectors.
• SIS synthon insertion site
• Rj "right" restriction site
• the Ri site can be unique or, if not unique, absent from the portion of the vector containing the SIS (or synthon) and the SM4/SM5 site, and delimited by the SIS (or the junction edge of the synthon) and the Ri site (e.g., the Rj that is cleaved to result in the ligatable end)].
• the Ri site can be a recognition sites for any Type II restriction enzyme that forms a ligatable end (e.g., usually cohesive ends). Usually the recognition sequence is at least 5-bp, and often is at least 6-bp. In one embodiment, the right restriction site is about 1 kb downstream of the SIS. In one embodiment of the invention, the Ri sites of the donor and acceptor vectors are not the same, but simply produce compatible cohesive ends when each is cleaved by a restriction enzyme.
• the SIS is a site suitable for LIC having a sequence with a pair of nicking sites recognized by a site-specific nicking endonuclease (usually the same endonuclease recognizes both nicking sites) and, positioned between the nicking sites, a restriction site recognized by a restriction endonuclease (to linearize the nicked SIS, consistent with the LIC strategy described above).
• a Vector Pair I vector has the following structure, where N] and N 2 are recognition sites for nicking enzymes (usually the same enzyme), R 2 is an SIS restriction site as discussed above, and Ri and SMI -5 are as described above, e.g., (SM2 or SM3) - N R 2 -N 2 - (SM4 or SM5) - Rj [II] [0161]
• a Vector Pair I vector is "occupied" by a synthon, and has the following structure, where 2Sj and 2S 2 are recognition sites for Type IIS restriction enzymes, Sy is synthon coding region, and Rj and SMI -5 are as described above, e.g., (SM2 or SM3) - 2S, - Sy - 2S 2 - (SM4 or SM5) - Ri [III] This is an intermediate construct useful for stitching.
• Vector pair II requires only one unique selectable marker on each vector in the pair (i.e., an SM found on one vector and not the other) although additional selectable markers may optionally be included.
• the stitching vectors have i) a synthon insertion site (SIS); ii) a "right" restriction site (Ri) as described above for Vector I, usually common to both vectors; iii) a "left restriction site” on each vector that may be the same or different (L or
• the spatial arrangement of these elements can be (SM4 or SM5) - (L or L') - SIS - (SM2 or SM3) - Rj [TV]
• the right restriction site (Ri) and left restriction site (L or L') are usually unique sites in the vector. In cases in which they are not unique, the additional sites are positioned so they do not interfere with the strategy described below and illustrated in Figure 3B.
• Recognition sites for any Type II restriction enzyme may be used, although typically the recognition sequence is at least 5-bp, often at least 6-bp. In one embodiment, the right restriction site is about 1 kb downstream of the SIS.
• the vectors also contain the conventional elements required for vector function in the host cell or useful for vector maintenance (for example, they may contain one or more of an origin of replication, transcriptional and/or translational control sequences, such as enhancers and promoters, and other elements).
• a Vector Pair II vector has the following structure, where Nj and N 2 , Ri, R 2 , L, L', and SM2 and 3 and SMI -5 are as described above, e.g., (L or V) - N R 2 -N 2 - (SM2 or SM3) - R, [V]
• a Vector Pair II vector comprises a synthon cloned at the SIS site and has the following structure, where 2S ⁇ and 2S 2 , Sy, Ri, L, L', SM2 and 3 are described above, e.g., (L or V) - 2S ⁇ - Sy - 2S 2 - (SM2 or SM3) - Ri [
• Figure 3 illustrates how the joining method shown above can be combined with a selection strategy to efficiently link a series of adjacent synthons (or other DNA units).
• Vector Pair I Figure 3A
• the vectors of the pair into which adjacent synthons have been cloned are digested with Ri (e.g., Xho I) and with either 2S ⁇ or 2S 3 (the site closest to the junction edges), and the products ligated.
• Ri e.g., Xho I
• 2S ⁇ or 2S 3 the site closest to the junction edges
• the vector containing the second, 3' adjacent synthon (donor vector) is restricted at the 5 '-synthon edge and Ri.
• the resulting products are ligated to reconstruct the vector containing 2 synthons, and selection is by antibiotic resistance markers SM2 and SM5.
• antibiotic resistance markers SM2 and SM5 By selecting for positive clones with a unique selection marker from both the donor and the acceptor plasmid, clones with the desired ligation product will be selected.
• the fransformation of cells e.g., bacterial cells such as E. coli
• selection of recombinant clones is well known, and the ligation products of the present invention can be manipulated using rountine techniques.
• synthons 1, 4, 6, and 7 can be cloned into the vector with the SM2+SM4 markers, and 2, 3, 5, and 8 can be cloned into the vector with the SM3+SM5 markers as summarized in Table 3.
• Table 4 shows a selection scheme for stitching a hypothetical 8-synthon module of sequence 1-2-3-4-5-6-7-8 using Vector Pair II. Synthons 1, 4, 6, and 7 can be cloned into the vector with the SM2 marker, and 2, 3, 5, and 8 can be cloned into the vector with the SM3 marker as summarized in Table 4. TABLE 4 SELECTION STRATEGY
• a combination of selectable markers and counter-selectable markers are used to facilitate rapid ligation of multiple DNA segments or units (e.g., synthon coding regions).
• An advantage of the method is that several DNA fragments can be ligated together simultaneously.
• "simultaneous" ligation of multiple polynucleotide fragments refers to ligation of multiple fragments in a single step, i.e., in the same container, generally without the necessity for intervening purification of intermediate cleavage or ligation products.
• This rapid ligation method is useful for joining a variety of types of DNA segments, including, for example, synthetic, naturally occurring, and chimeric DNAs.
• the number of segments simultaneously ligated is sometimes at least three, often at least four, and more often at least five.
• the number of segments simultaneously ligated is in a range defined by a lower value selected from 3, 4, 5, and 6 and an upper value independently selected from 4, 5, 6, 7, 8, 9 and 10, where the upper value is greater than the lower value.
• a wide size range of segments can be ligated according to the present method (e.g., fragments ranging from 30 bp to over 1 kb in length).
• the segments to be ligated are synthetic synthons ranging in length from about 300 to about 700 bp, for example, from about 400 to about 600 bp in length. Terminology
• any given ligation of three or more DNA segments two of the segments can be considered to lie at the ends of the resulting ligation product, and the other segment or segments will lie between those ends. Based on these positions, the DNA fragments can be referred to as either "end segments” or “internal segments.” It will be understood that the "end segments” may, but generally do not, have free termini (for example, they may be contiguous with adjacent vector sequences or ligated together to form a circular product). The two end segments can be further designated as the "upstream” and "downstream” end segments.
• the designation of one end segment as “upstream” and a second end segment as “downstream” can be arbitrary, although, if the segments contain a coding sequence, "upstream” usually refers to the 5' direction of the coding strand, consistent with general convention.
• upstream usually refers to the 5' direction of the coding strand, consistent with general convention.
• the furthest upstream DNA fragment is referred to as “Segment 1” and the remaining DNA segments are numbered consecutively in the order in which they are found in polynucleotide resulting from the ligation.
• the segments are numbered 1, 2, 3 and 4, with 4 being the downstream end segment.
• polynucleotides (hereinafter referred to as “synthons”) containing the segments to be ligated (hereinafter referred to as “synthon coding regions”) are cloned into one of three types of assembly vectors, depending on whether the synthon comprises an "upstream” end segment (cloned into a Type 1 vector), a “downstream” end segment (cloned into a Type 2 vector) or an "internal” segment (cloned into a Type 3 vector).
• Synthons polynucleotides containing the segments to be ligated
• Type 1 , Type 2 and Type 3 vectors contain a synthon insertion site and a counter-selectable marker.
• Type 1 and Type 2 vectors additionally contain "unique selectable markers.”
• Type 3 vectors additionally contain a "propagation selectable marker.”
• Type 1 and Type 2 vectors also contain a "propagation selectable marker.”
• Synthon insertion sites (SISs) are described above (e.g., Section 4.2.1) and include sites suitable for ligation-independent cloning as well as conventional cloning methods.
• the SIS is flanked by recognition sites for rare cutting endonucleases (e.g., Notl, Pad, I-Ceu I R0699, 1-Sce I R0694 and the like; see Figure 20).
• the rare cutting sites are useful for confirming the size of ligation products and for other manipulations of ligation products.
• a Type 1 vector into which a synthon has been cloned (e.g., an "occupied assembly vector”) can be called a "Type 1 DNA molecule.”
• a Type 2 vector into which a synthon has been cloned can be called a "Type 2 DNA molecule”
• a Type 3 vector into which a synthon has been cloned can be called a "Type 3 DNA molecule.”
• the Type 1, Type 2, and Type 3 DNA molecules therefore comprise both synthon and vector sequences.
• a "propagation selectable marker” (“SM”) is a selectable marker (e.g., gene conferring drug resistance) which is useful for the initial cloning of synthons into the vectors, screening for transformants, and other uses.
• the SM is found on Type 1 and Type 2 vectors as well as Type 3 vectors.
• Using a common SM in each of the vector types allows convenient coselection of different vectors at the same time, and has other advantages; accordingly, in one embodiment, the SM is the same for all three vectors.
• the "unique selectable markers" of the Type 1 and Type 2 vectors are used for selection during routine cloning steps and thus substitute for a SM on these vectors.
• CSM Counter-selectable markers
• the Type 1 and Type 2 vectors each contain a "unique selectable marker" (U- SM).
• "unique” means the marker is not found on a different type vector used in the ligation reaction.
• the U-SM of the Type 1 vector is different from the U-SM of the Type 2 vector and both are different from the propagation selectable marker(s).
• the unique selectable marker on Type 1 vectors are labeled "U-SM2" or "U-SM4" and the unique selectable marker on Type 2 vectors is called “U-SM3" or "U-SM5.”
• the Type 1 and Type 2 vectors also contain a cleavage site ("R") positioned between the counter-selectable marker (CSM) and the unique selectable marker (U-SM).
• the cleavage site is an endonuclease cleavage site that produces a ligatable end upon cleavage.
• the R sites of the Type 1 and Type 2 vectors preferably are the same, or are different but generate compatible (ligatable) overhangs upon endonuclease digestion.
• the R site is a cleavage site of a Type IIS restriction endonuclease.
• the R site is a Type IIS cleavage site, it is sometimes useful to position the enzyme recognition site so that the recognition site is retained in the final ligation product.
• the R site is a cleavage site of a Type IIS restriction endonuclease that also cleaves at the edge or edges of a synthon coding region or region to produce a ligatable end that is ligated to an adjacent synthon coding sequence.
• the Type 1 , Type 2 and/or Type 3 vectors may have a pair of endonuclease cleavage sites flanking the SIS (or synthon). These sites are useful for manipulation of ligation products.
• Not I and Pac I sites are shown (for illustration and not limitation). (These sites are not shown in Figures 20B, C or D, but are optionally present).
• the flanking endonuclease sites are recognized by "rare cutter" endonucleases.
• the relative positions of the counter-selectable marker CSM, the unique selectable marker U-SM, the cleavage site R, and the synthon inserted at the SIS differs in the Type 1 and Type 2 vectors:
• the order is 5'- Synthon-3' ⁇ CSM- R- ⁇ U-SM while in the second vector the order is 5'-Synthon-3'- U- SM->R- CSM, where the 5 '-3' orientation of the synthons is consistent with their orientation in the resulting multisynthon (and usually corresponding to the 5 '-- 3' polarity of the coding strand).
• Synthons are prepared (e.g., by assembly PCR) and cloned into vector SISs as described above. As also discussed above, the synthons include endonuclease cleavage sites that, upon cleavage, produce ligatable ends at the junctions of adjacent synthon coding regions. Each synthon flanking region is designed so that digestion with the appropriate endonuclease results in creation of ligatable ends (located at the edge of the synthon coding region) that are specific for the adjacent synthon.
• Each synthon or synthon coding region has two ends or edges.
• an endonuclease cleavage site at one end gives rise (upon treatment with endonuclease) to the cohesive end that is ligated to the adjacent synthon in the final ligation product in any particular round of ligation.
• the internal segment(s) comprise endonuclease cleavage site at each end, each of which gives rise (upon treatment with endonuclease(s)) to the cohesive ends ligated to the two adjacent synthons.
• the two sites in an internal segment are referred to as the 5-prime cleavage site and the 3-prime cleavage site.
• the Type 1 assembly vector containing the upstream end segment is digested with one or more enzymes to cleave at (i) the R site and (ii) one edge of the synthon coding sequence, to produce to ligatable ends.
• the edge of the synthon coding sequence that is cleaved is that edge that is subsequently to be joined to the adjacent segment, and is typically the 3' end of the synthon coding sequence.
• the ligatable end at the R site is ligatable to the end produced in the Type 2 assembly vector upon digestion at the R site of that vector.
• the ligatable end at the edge of the synthon coding sequence is ligatable to the end produced in the adjacent (e.g., downstream), internal synthon.
• the Type 3 assembly vector(s) containing internal segment(s) is digested with one or more enzymes to cleave and produce ligatable ends at both edges of the synthon coding region.
• the Type 2 assembly vector containing the downstream end segment is digested with one or more enzymes to cleave at (i) the R site and (ii) one edge of the synthon coding sequence to produce to ligatable ends.
• cleavage is at the edge of the synthon coding sequence is that edge that is subsequently to be joined to the adjacent segment, and is typically the 5' end of the synthon coding sequence for the Type 2 vector.
• the ligatable end at the R site is ligatable to the end produced in the Type 1 assembly vector upon digestion at the R site of that vector.
• the ligatable end at the edge of the synthon coding sequence is ligatable to the end produced in the adjacent (e.g., upstream) internal synthon.
• Endonuclease digestion of each individual vector can be carried out separately (e.g., in separate tubes, chambers, or wells) and the cleavage products combined subsequently for ligation.
• multiple vectors e.g., the Type 1 and 2 and all of the Type 3 vectors containing segments for ligation
• the endonucleases used are active under compatible conditions (e.g., temperature, pH, ion concentration, etc.).
• the cleavage sites at all of the synthon edges for which cleavage is described above, as well as the cleavage sites for the R sites of the Type 1 and Type 2 vectors are cleavage sites for the same enzyme (e.g., the same Type IIS restriction enzyme).
• the same enzyme e.g., the same Type IIS restriction enzyme.
• Such a design is advantageous insofar as there may be a reduction in the number and amount of endonucleases, buffers, etc. required for the cleavage step.
• multiple different enzymes may be used simultaneously or sequentially in the same tube, with buffer adjustments, enzyme inactivation, and the like as necessary.
• Figure 20B illustrates a four-segment ligation of synthons 1, 2, 3 and 4 to make a multisynthon.
• 1.1 , 1.2 and A-F are endonuclease recognition sites.
• the Type 1, 2 and 3 DNA molecules (occupied assembly vectors) are digested by endonucleases that recognize sites A-F and R.
• A-F and R are Type IIs restriction endonuclease recognition sites, and are optionally the same enzyme.
• the resulting fragments are joined by annealing and ligation of cohesive ends, cells are transformed with the ligation products, and transformants that express U-SM2 and USM3 but not CSM1 are selected.
• the product of the ligation and selection is shown in Figure 20B. Note that endonuclease recognition sites 1.1 and 1.2 may be used in subsequent rounds of ligation as illustrated in Figure 20C.
• a first multisynthon (synthons 1 --> 4) is prepared as just described.
• a second multisynthon (synthons 5-> 8) is prepared as just described except that the Type 1 and Type 2 vectors used in the first ligation round comprise a different set of unique selectable markers (compare the first and second pairs of vectors shown in Figure 20A) and the upstream and downstream end segments (synthons 5 and 8) are distally bound by endonuclease recognition sites 2.1 and 2.2 (e.g., in the synthon coding regions).
• Figure 20D shows ligation of four synthons using Type 1, 2 and 3 vectors in which the SM is carb (carbenicillin resistance), the U-SMs are tet (tetracycline resistance) and Jan (kanamycin resistance), the CSM is araB (ribulose sensitivity), the R sites are both recognized by Bsa I, and the other endonuclease recognition sites are Bsa I, Eco RI and Bbs I, as shown.
• the SM is carb (carbenicillin resistance)
• the U-SMs are tet (tetracycline resistance) and Jan (kanamycin resistance)
• the CSM is araB (ribulose sensitivity)
• the R sites are both recognized by Bsa I
• the other endonuclease recognition sites are Bsa I, Eco RI and Bbs I, as shown.
• an advantage of the present method is that it is not necessary to isolate or purify segments prior to ligation.
• the selection system of the invention allows rapid and efficient (i.e., high proportion of correct vs. incorrect constructs) isolation of the desired product.
• additional steps can be taken to reduce or eliminate undesired ligation products, including, for example, (i) digestion of vector sequences (e.g., sequences not intended to be part of the ligation product) using an enzyme(s) that cuts multiple times in the vector; (ii) use immobilizable primers that specifically hybridize to sequences not intended to be ligated (e.g. vector sequences) to remove unwanted vector sequences.
• biotinylated primers may be hybridized to the unwanted vector sequences and the resulting complex removed using streptavidin beads.
• the primers are labelled to magnetic beads.
• segments are ligated together by combining aliquots from each of the assembly vector digestions (if digested separately) and adding ligase (e.g., T4 DNA ligase) in an appropriate buffer, or, if the assembly vectors are pooled for digestion, adding ligase to the pooled reaction mixture or to an aliquot of the pooled reaction mixture. Generally prior to addition of ligase, the endonucleases will be inactivated (e.g., incubation at 65-80°C for 20 m or at 25°C for 15 h). [0197] Cells (e.g., E.
• U-SMs unique selectable markers
• cells may be selected using 50 Eg/ml kanamycin, 25 Hlg/ml chloramphenicol, and 5% sucrose. Further lizations
• a pair of multisynthons each prepared as described above can be combined to generate a larger polynucleotide.
• the two constructs resulting from the first rounds of multisegment ligation each are digested at the cleavage site defining the junction between the two multisynthons and at the "R" sites.
• the resulting digestion products are ligated together, cells transformed with the ligation product, and selected for using the two unique selectable markers.
• the adjacent synthon edges can share common sites B, C, D, E, F, G and H as follows: A-l- B, B-2-C, C-3-D, D-4-E, E-5-F, F-6-G, G-7-H, H-8-X. See Figure 5 for illustration.
• the vector is cleaved by digestion at L' to reduce formation of undesired ligation products. It will be apparent that when the resulting 2-synthon product is used in subsequent steps as a donor vector, it can be cleaved by digestion at L.
• Method R can be carried out using the same vector pairs as are useful for Method S.
• a Vector Pair I vector comprises a synthon cloned at the SIS site can have the following structure (where R 3 and R 4 are restriction or other endonuclease sites at the edges of the synthon, and the other abbreviations are as described previously): - (SM4 or SM5) - R 3 - Sy - t - (SM2 or SM3) - Rj [VII] This is an intermediate construct useful for stitching.
• the synthetic module genes of the invention will encode a polypeptide with a desired amino acid sequence and/or activity, and typically • use the codon preference of a specified expression host, • are free from restriction sites that are inconsistent with the stitching method (e.g., the Type IIS sites used in stitching Method S) and/or are comprised of synthons free from restriction sites that are inconsistent with the stitching method (e.g., the Type II sites used in stitching Method R) and/or are free from restriction sites that are inconsistent with the construction of open reading frames and gene libraries (as described below), • contain useful (e.g., unique) restriction sites or sequence motifs at specific locations (e.g., region encoding domain edges, synthon edges, module boundaries, and within synthons).
• useful e.g., unique
• a GeMS process generically applicable to the design of any gene has several of the following features: (i) restriction site prediction algorithms; (ii) host organism based codon optimization; (iii) automated assignment of restriction sites; (iv) ability to accept DNA or protein sequence as input; (v) oligonucleotide design and testing algorithm; (vi) input generation for robotic systems; and (vii) generation of spreadsheets of oligonucleotides.
• GeMS executes several steps to build a synthetic gene and generate oligonucleotides for in vitro assembly. Each of these steps are closely connected in the overall program execution pipeline. This allows the gene design to be executed in a high- throughput process as shown in Figure 8.
• a GeMS process initiates with an input 800 of (i) an amino acid sequence of a reference polypeptide and (ii) parameters for positioning and identity of restriction sites or desired sequence motifs.
• a DNA sequence of the reference polypeptide is input and translated to the corresponding amino acid sequence.
• the amino acid/DNA sequence are input from publicly available databases (e.g., GenBank), in one embodiment the sequence is verified (by independent sequencing) for accuracy prior to input in the GeMS process.
• a GeMS process according to the present invention comprises a first series of steps 810 wherein the amino acid sequence is used as a reference to generate a corresponding nucleotide sequence which encodes the reference polypeptide ("reverse translated").
• Further processes in the first series of steps include codon randomization wherein additional nucleotide sequences are generated which encode a same (or similar) amino acid sequence as the reference polypeptide using a random selection of degenerate codons for each amino acid at a position in the sequence.
• the process may optionally include optimization of codon usage based on a known bias of a host expression organism for codon usage.
• the codon-randomized DNA sequence generated by the software is further processed for introduction of restriction sites at specific location, and removal of undesired occurrences of sites in subsequent steps.
• sites may be unique (within the entire gene, or a portion of the gene) or useful based on position and spacing (e.g., sites useful for synthon stitching using Method R, which need not necessarily be unique).
• a user inputs positions of preferred restriction sites in the sequence.
• the input optionally comprises the identity of an appropriate host organism for expression of the synthetic gene and its preference for codon usage.
• the input may optionally include one or more lists of annotated restriction sites or other sequence motifs desired to be inco ⁇ orated in the nucleotide sequence of the gene (e.g., at module/domain/synthon edges), and annotated restriction sites to be removed or excluded from the gene (e.g., recognition sites for Type IIS enzymes used in stitching).
• acceptable ranges of synthon sizes typically about 300 to about 700 basepairs
• synthon flanking sequences e.g., sequences useful for ligation independent cloning, for example, annealing of "universal" UDG primers.
• step 920 the amino acid sequence of the reference polypeptide segment is converted (reverse-translated) to a DNA sequence using randomly selected codons, such that the second DNA sequence codes for essentially the same protein (i.e., coding for the same or a similar amino acids at corresponding positions).
• the random choice of codons reflects a codon preference of the selected host organism.
• the codon optimization and randomization are omitted and the DNA sequence derived from the database is directly processed in the subsequent steps. The codon randomization and optimization processes are described in greater detail in Figures 10A and 10B and the accompanying text.
• preselected restriction sites and their positions are input in step 930.
• the GeMS program then identifies positions for insertions of the specified sites and identifies positions from which unwanted occurrences of specific restriction sites are to be removed.
• one or more parameters for positions of restriction sites and specified characteristics of the sites are input in step 934.
• GeMS identifies all possible restriction sites within the sequence in step 936.
• the program also suggests a unique set of restriction sites according to the predetermined parameters (such as spacing, recognition site, type, etc.) in step 936.
• the regions suggested are selected for their presence within or adjacent to synthon fragment boundaries.
• each synthon sequence is generated as overlapping oligonucleotides of a specified length with a specified amount of overlap with its two adjacent oligonucleotides in step 970.
• the length of the oligonucleotides may be about 10, 15, 20, 30, 40, 50, 60, 70, 80, 90 or 100 nucleotides.
• the length of the overlap may be about 5, 10, 15, 20, 25, 30, 35, 40 or 50 nucleotides.
• the lengths of the overlap may not be precise and a variation by 1, 2, 3, 4 or 5 between several oligonucleotides comprising adjacent synthons is acceptable.
• each synthon is designed as oligonucleotides of overlapping 40-mers with about a 20 base overlap among adjacent oligonucleotides.
• the overlap may vary between 17 and 23 nucleotides throughout the set of oligonucleotides. An option to design these oligonucleotides based on an uniform annealing temperature is also available.
• the entire candidate module sequence can be checked in any way desired (repeats, etc.), with the possibility of triggering redesign of individual synthons.
• duplicated regions are removed although the random choice procedure makes occurrence of substantial repeats unlikely.
• the software also edits the sequence to remove clustered positioning of rare codons. Since each redesign uses a random set of codons, synthon fragments pass these tests in relatively few iterations. [0224] Once all fragments have passed the tests, GeMS reassembles the fragments in predetermined order and validates the restriction sites and DNA sequence by comparison with the original input sequence.
• a method in accordance with the present invention comprises algorithms capable of performing one or more of the following subroutines:
• the rationale is to choose a cut-off value that eliminates most rare codons. In one embodiment, this is done by visual inspection of the modified codon tables and selecting a cut-off value that eliminates most rare codons without affecting the preferred codons.
• Each codon is tested for a codon preference value above the cut-off value in step 1022. All codons with N below the user-defined cut-off value are rejected in step 1024.
• codons with N values above the cut-off value are pooled and the N values normalized in step 1030 such that the sum of the N values is one (1).
• a codon preference table for the synthetic gene is generated in step 1040.
• the user indicates acceptance of the output according to one embodiment. If the list of restriction sites generated is accepted by the user, the process is transferred to the GeMS codon-optimization routine. If the result is not acceptable to the user, the sub-routine is repeated while allowing the user to modify the parameters manually. The process is repeated until a signal indicating acceptance is received from the user. After the user accepts the restriction sites, the sequence is transferred to the next routine in the GeMS module to perform the subsequent procedures. [0233] 3. Removal of Restriction Sites — Restriction sites that are selected in steps 932 or 938 of the GeMS program (see Figure 9) are cleared from the codon optimized gene sequence as shown schematically in Figure 11.
• a sub-routine of the present process removes selected restriction sites that are specified and input 1100 with the randomized-optimized gene sequence.
• the sub-routine identifies the pre-selected restriction sites in the codon-optimized gene sequence and identifies their positions in step 1110.
• the open reading frames comprising the recognition site are examined for the ability to alter the sequence and remove the restriction site without altering the amino acid encoded by the affected codon at the restriction site in step 1120. If the reading frame is open, the first codon of the recognition site is replaced with a codon encoding the same or a similar amino acid in a manner that removes the restriction site sequence.
• the sub-routine shifts to the next available codon and continues until the restriction site is removed. Since a restriction site may encompass up to 6 nucleotides, removal of a site may involve analysis of up to three amino acid codons. Removal of restriction sites is performed in a manner which retains the identity of the encoded amino acid in step 1130. The sub-routine generates a randomized-optimized gene sequence from which selected restriction sites have been removed without altering the amino acid sequence 1140.
• the synthon When such sequence is present in the synthon, it can be cleaved remotely by a Type IIS restriction enzyme and the overhang thus generated is available for ligation with a DNA fragment which has been cleaved with a Type II restriction enzyme to generate the complementary overhang.
• the substituted sequence is translated and the resulting amino acid sequence is compared in step 1230 with the sequence of the reference amino acid (see 1052 in Figure 10B).
• the substituted sequence is translated and the resulting amino acid sequence is compared in step 1230 with the sequence of the reference amino acid (see 1052 in Figure 10B), comparing the sequences for identity of the amino acid sequences.
• the codon table may be re-examined in step 1240A for codons compatible with both the amino acid sequence and the substituted sequence, and compatible with the desired pattern of restriction sites and sequence motifs or other patterns. If any compatible codons are found, one is chosen from the list of such codons according to user preference (for example, by use of relative probabilities in a codon table), and inserted as replacement for the undesired codon; the program returns to step 1240. If the amino acid sequence is altered, and not repairable by the procedure described in step 1240A, the program proceeds to step 1242.
• the user in step 1242 has the option of rejecting the output in step 1244 and repeating the process of nucleotide substitutions at the selected position.
• the user replaces in step 1246 an amino acid with a similar amino acid and manually accepts the output.
• the sequence generated following introduction of the restriction sites is then checked for translational errors in step 1250.
• a randomized-optimized synthetic gene sequence with selected restriction sites removed and other selected restriction sites inserted is provided in step 1260.
• sequence motifs other than restriction sites can be "inserted” or "removed” (i.e., the oligonucleotides, synthons and genes can be designed to include or omit the sequence motifs from particular locations).
• regions of sequence identity are useful for construction of multisynthons (see, e.g., Exemplary Construction Method 2 in Section 6.4.3, below) and can be included at specified locations of synthetic genes).
• the input to GeMS has each of the restriction sites tagged as either a domain edge or synthon edge along with their positions. Based on these criteria, this step 1320 (see Figure 13) of the program pipeline divides the entire gene sequence into a number of synthons in one embodiment. In another embodiment, a preferred synthon size is input. Overlapping oligonucleotide sequences are generated in step 1320 to comprise the synthon coding region as well as the synthon flanking sequences.
• a synthetic gene sequence 1312 is input along with parameters in step 1310 specifying lengths of oligonucleotides and the extent of overlap between adjacent oligonucleotides.
• the synthetic gene sequence is divided in step 1320 into a plurality of oligonucleotide sequences of specified length with overlaps allowing a selected number of bases to pair with adjacent strands.
• Each oligonucleotide is aligned with the synthetic gene sequence 1312 and the extent of alignment is determined in step 1330.
• the extent of alignment (match score) is compared in step 1332 to a predetermined sequence specificity cutoff value for acceptable degree of alignment.
• the synthetic gene is a synthon.
• Oligonucleotides comprising a synthon include oligonucleotides specific for the synthon coding region as well as the synthon flanking sequences.
• Each synthon is comprised of oligonucleotides designed as a set of oligonucleotides each having overlaps of complementary sequences with its two adjacent oligonucleotides on either side.
• the selection of the length of oligonucleotides take into account several factors including, the efficiency and accuracy of synthesis of oligonucleotides of specific lengths, the efficiency of priming during assembly PCR, annealing temperatures and translational efficiency.
• a 40-mer size of each oligonucleotide is selected with an overlap of about 20 nucleotides with adjacent oligonucleotides.
• Each oligonucleotide is designed as two approximately equal halves (in this instance, two 20-mer sections), wherein each half must meet the criteria for interactions (e.g., annealing, priming) with the two adjacent oligonucleotides that overlap with either half.
• the selection of a 40-mer sequence further reflects the accuracy of chemical synthesis of oligonucleotides of that length.
• the present invention relates to assembly of the overlapping oligonucleotides by a PCR reaction
• the oligonucleotides may be assembled enzymatically by a combination of DNA ligase and DNA polymerase enzymes.
• longer oligonucleotides may be used with shorter overlaps.
• the overlaps may leave gaps of 5, 10, 15, 20 or more nucleotides between the regions of an oligonucleotide that are complementary to its two adjacent oligonucleotides. Such gaps can be repaired by a DNA polymerase enzyme and the synthon comprised by the oligonucleotides can then be assembled by a DNA ligase mediated reaction.
• Oligonucleotide Design Criteria The design of suitable oligonucleotide sets are based on a number of criteria. Two criteria used in the design are annealing temperature and primer specificity.
• Optimum Annealing Temperature User-defined ranges for annealing temperature (preferably 60 - 65°C) and oligonucleotide overlap length are input. To increase temperature, the size of the oligonucleotide overlap length is increased and vice- versa.
• the GeMS program designs the oligonucleotides within specified annealing temperature boundaries. The criterion is a uniform (preferably, narrow range of) annealing temperature for the entire set of oligonucleotides that are to be assembled by a single PCR reaction.
• Annealing temperature is measured using the nearest neighbor model described by Breslauer
• each of the overlapping oligonucleotide sequences generated for each synthon (or synthetic gene) is subjected to primer specificity tests against the entire synthon.
• each of the oligonucleotide sequences in a synthon is tested by alignment against the entire synthon sequence. Alignment is determined by comparing the numbers of matches and mismatches between the oligonucleotide sequence and the sequence of the synthon. Oligonucleotides that align with a degree of alignment higher than a predetermined value are selected for synthesis. In one embodiment, this is performed by aligning the oligonucleotide sequence against the synthon sequence starting at position 1 and sliding it across the length of the synthon sequence one base at a time.
• an oligonucleotide sequence is determined to be unsuitable for use according to the following series of steps:
• Step I align the last three (3) bases of both the oligonucleotide sequence and synthon reference sequence such that they are identical;
• Step 2 count the number of matches and mismatches in the aligned sequences with matches being identical bases in both sequences at the same position;
• Step 3 calculate the ratio of matches to the total number of bases forming the overlap or alignment.
• oligonucleotide is suitable for synthesis.
• oligonucleotides whose threshold value falls lower than the user-defined value can be subjected to manual modification of its sequence to increase the extent of alignment and meet the threshold requirement.
• Oligonucleotide Quality Testing The software checks for any undesired degree of aberrant priming among the oligonucleotides of each synthon. If present, it repetitively redesigns synthons in which this occurs until the design is improved. In difficult cases, it reports the results and prompts user to manually repair the errors.
• Input Validation Routines One or more user input validation routines can be implemented to run independently in parallel with the synthon design routines. These perform validation checks on instructions input by the user. These routines validate instructions typically input by a user during a step of the GeMS process and include validation of restriction site positions based on the site prediction algorithm, frame shifts and synthon boundaries. Identification of errors at the input stage prevents the user from providing any input that results in a faulty design.
• Output Validation Routine A program output validation routine can be used to reduce the time to validate the designed synthons. This allows the end-to-end design process to operate in a high-throughput manner. This program reassembles the designed synthons while maintaining the correct order and recreates a synthetic gene. The new synthetic gene is then translated to its amino acid sequence and compared with the original input protein sequence for possible errors. The restriction site pattern for the assembled sequence is verified as being the one desired. The restriction site pattern for each designed synthon (including the synthon-specific primers) is verified as well. Other quality tests can be preformed, including tests for undesired mRNA secondary structure and undesired ribosome start sites.
• the GeMS software is implemented to execute within a web- browser application making it a platform-neutral system. Its design is based on the client- server model and implemented using the Common Gateway Interface (CGI) standard.
• CGI Common Gateway Interface
• All CGI scripts and the application programming interface (API) for GeMS were implemented in Python version 2.2. Development, testing and hosting of the application was performed on a 1.0 GHz Intel Pentium III based processor server running RedHat Linux version 7.3. The web interface runs on the Apache HTTP Server version 2.0.
• the annealing temperature module in the GeMS API utilizes the EMBOSS software analysis package (Rice, P. Longden, I.
• the invention provides a computer readable medium having computer executable instructions for performing a step or method useful for design of synthetic genes as described herein.
• Synthetic genes designed and/or produced according to the methods disclosed herein can be expressed (e.g., after linkage to a promoter and/or other regulatory elements).
• a synthetic gene is linked in a single open reading frame with another synthetic gene(s) to encode a "fusion polypeptide.” It will be recognized that the DNA encoding the fusion polypeptide is itself a synthetic gene (generated from the linkage of smaller genes).
• multiple different open reading frames can be co- expressed (or their protein products combined in vitro) to form multiprotein complexes.
• Methods for producing polypeptide-encoding synthetic genes comprising combinations of PKS modules and/or accessory units include by designing and stitching together synthons that together encode a gene encoding the combination using methods discussed above, (e.g., in Section 4).
• two or more synthetic genes that can encode different portions of the single polypeptide may be joined by conventional recombinant techniques (including ligation-independent methods, linker-mediated methods, and other methods) using sites or sequence motifs located (e.g., engineered) at particular locations in the gene sequences (e.g., in regions encoding termini of modules, domains, accessory units, and the like).
• One important new benefit of the design and synthetic methods of the present invention is the ability to control gene sequences to facilitate the cloning of modules, domains, etc.
• a particularly useful ramification of these methods is the ability to make multiple large libraries of genes encoding structurally or functionally similar units (for example modules, accessory units, linkers, other functional polypeptide sequences), in which restriction sites or other sequence motifs are located an analogous positions of all members of the library.
• a PKS module gene can be synthesized with unique restriction sites at the termini (e.g., Xba I and Spe I sites) facilitating cloning into the same sites in a vector.
• the invention provides multiple large libraries of genes encoding polypeptides comprising regions (linkers) that allow the polypeptides to associate with other polypeptides encoded by members of the library or by members other libraries.
• the invention provides, for example, vectors and vector sets that can be used for manipulation, expression and analysis of numerous different polypeptide segment-encoding genes.
• the invention provides useful vectors (referred to as ORF vectors) that facilitate preparation of libraries of genes encoding multimodule constructs.
• ORF vectors useful vectors
• the following sections describe exemplary methods for making and using vectors and vector libraries comprising ORFs encoding PKS modules and accessory units.
• Section 6.2 describes how libraries can be used to analyse interactions between modules and other polypeptide units. This section is intended to illustrate how libraries can be constructed and used. Section 6.3 discusses module and linker combinations. Section 6.4 describes certain ORF vectors and methods for constructing them.
• the invention provides methods for expression of PKS module- encoding genes in combinations not found in nature.
• Such novel module architecture enables production of novel polyketides, more efficient production of known polyketides, and further understanding of the "rules" governing interactions of PKS modules, domains and linkers.
• Combinations of "heterologous" modules i.e. modules that do not naturally interact) may not be productive or efficient. For example, at a heterologous module interface, the product of the first module may not be the natural substrate for the second or subsequent modules and the accepting module(s) may not accept the foreign substrate efficiently.
• libraries of vectors are prepared in which the members of the library comprise the same extension module(s) but comprise different accessory units (e.g., different loading modules and/or different linker domains and/or different thioesterase domains).
• the invention provides methods for synthesizing an expression library of PKS module-encoding genes by: making a plurality of different synthetic PKS module-encoding genes (e.g., as described herein) and cloning each gene into an expression vector.
• the library includes at least about 50 or at least about 100 different module-encoding genes.
• such libraries are used in pairs to identify productive interactions between pairs or combinations of PKS modules.
• a first ORF library comprises vectors comprising an open reading frame encoding a loading domain (LD), a PKS module (Mod), and a left linker (LL).
• LD loading domain
• Mod PKS module
• LL left linker
• different members of the library encode the same LD and LL, but different modules, i.e.: [LD-Mod-LL] register [Exemplary Library I] where n is usually > 20.
• a second ORF library comprises vectors comprising an open reading frame encoding a right linker (RL), a module (Mod), and a thioesterase domain (TE), where different members of the library encode different modules, i.e.: [RL-Mod-TE]quot [Exemplary Library II] where n is usually > 20.
• the terms "right linker” (RL) and “left linker” (LL) refer to inte ⁇ olypeptide linkers that allow two polypeptides to associate.
• the appropriate sequence of transfers can be accomplished by matching the appropriate C-terminal amino acid sequence of the donating module with the appropriate N-terminal amino acid sequence of the inte ⁇ olypeptide linker of the accepting module. This can be done, for example, by selecting such pairs as they occur in native PKS.
• two arbitrarily selected modules could be coupled using the C-terminal portion of module 4 of DEBS and the N-terminal of portion of the linking sequence for module 5 of DEBS.
• novel combinations of linkers or artificial linkers can be evaluated and used.
• each of the two libraries shown contains four members, each member containing a gene encoding a different module, i.e., module A, B, C or D ("ModA,” “ModB,” “ModC,” “ModD”).
• module A, B, C or D Module A, B, C or D
• Modules A, B, C and D Modules A, B, C and D
• ModA Modules A, B, C and D
• LD-ModB-LL RL-ModB-TE LD-ModC-LL RL-ModC-TE
• modules e.g., pairwise combinations
• a suitable host e.g., E. coli engineered to support PKS post-translational modification and substrate Co-A thioester production
• product triketides may be analyzed by appropriate methods, such as TLC, HPLC, LC-MS, GC-MS, or biological activity.
• the library members may be expressed individually and Library I - Library II combinations can be made in vitro.
• Affinity and/or labelling tags may be affixed to one or both termini of the module constructs to facilitate protein isolation and testing for activity and physical interaction of the module combinations.
• the productive pair can be combined and tested in new pairwise combinations. For example, if LD-ModA-LL + RL- ModD-TE was productive, the construct LD-ModA-ModD-LL could be synthesized and tested in combination with members of Library II. Similarly, a third library, containing [LL- Mod-RL] n constructs, can be used. A number of other useful libraries made available by the methods of the present invention will be apparent to the practitioner guided by this disclosure.
• the interactions of accessory units and modules can be assessed by keeping the module gene constant and varying the accessory units (e.g., using a library in which different members encode the same extension module(s) but different loading modules or linkers).
• module genes can be expressed with native or heterologous linker sequences.
• useful fusion proteins of the invention can include a number of elements. Examples include: construct # structure 1. LD-Modl-LL 2. LD-Mod2-LL H 3. RL-Mod3-TE 4. RL H -Mod4-TE 5. RL-Mod5-Mod6-LL 6.
• LD refers to a PKS loading module
• TE refers to a thioesterase domain
• RL and “LL” refer to PKS inte ⁇ olypeptide linkers
• subscript “H” means a “heterologous” linker
• * indicates that a heterologous AKL (ACP-KS Linker, see definitions, Section 1) is present
• Mod refers to various PKS modules.
• the modules can differ not only with respect to sequence and domain content, but also with regard to the nature of the inte ⁇ olypeptide and intermodular linkers. A general discussion of PKS linkers is provided in Section 1, above, and the references cited there.
• PKS extension modules in different polypeptides can be linked by "inte ⁇ olypeptide” linkers (i.e., RL and LL) found (or placed) and multiple PKS extension modules in the same polypeptide can be linked by AKLs.
• Extension modules used in the constructs can correspond to naturally occurring modules located at the amino terminus of a naturally occurring polypeptide or other than the amino-terminus, and be placed at the amino terminus of a polypeptide encoded by a synthetic gene (e.g.,. Mod3) or other than the amino-terminus (e.g., Mod 6).
• useful assembly vectors may contain restriction sites in addition to those described in Section 4 positioned on either side of the SIS (and thus on either side of the module contained in the occupied assembly vectors). Since these flanking restriction sites (“FRSs") are usually absent from the sequences synthetic module genes (i.e., "removed” during gene design) it is generally advantageous to use rare sites (e.g., 8-bp recognition sites).
• FSSs flanking restriction sites
• any of a large numbers of sites recognized by Type IIS enzymes can be used for sites 7 and 8; any of a variety of sites can be used for sites 3 and 4, although rare sites (e.g., with 7 or 8 base pair recognition sequences) are preferred.
• any number of sites can be used in place of Xba I and Spe I, provided that compatible cohesive ends are generated by digestion of the sites (and preferably, neither site is regenerated upon ligation of the cohesive ends).
• Xba I and Spe I provided that compatible cohesive ends are generated by digestion of the sites (and preferably, neither site is regenerated upon ligation of the cohesive ends).
• all of these sites are useful, not all are required for the present methods, as will be apparent to the reader of ordinary skill. In many embodiments one or more of the sites is omitted.
• a multisynthon transferred from an assembly vector to an ORF vector is sometimes referred to as, simply, a "module.”
• _ ⁇ and ⁇ indicate a nucleotide sequence encoding a structural or functional polypeptide segment such as a non-PKS polypeptide segment (e.g., NRPS modules) or PKS accessory unit.
• ⁇ can be a gene sequence encoding a loading module or inte ⁇ olypeptide linker and
• can be a gene sequence encoding a thioesterase domain, other releasing domain, inte ⁇ olypeptide linker, and the like.
• an ORF vector in which the 1-2 fragment comprises a methionine start codon and a synthetic gene sequence encoding the DEBS loading domain, the central region comprises a synthetic gene sequence encoding DEBS modules 2 and 3, and the C-terminal region comprises a synthetic gene sequence encoding a DEBS TE domain would encode a polypeptide comprising the DEBS N-LM-DEBS2-DEBS3-TE-C (all contiguous synthetic polypeptide-encoding gene sequences described herein are in-frame with each other).
• Coding sequences of accessory units are known (see, e.g., GenBank) and synthetic accessory unit genes can be made by synthon stitching and other methods described herein. Exemplary methods for construction of ORF vectors with such N-terminal and C- terminal regions are described below.
• the construction method itself does not require either 1 or 6 to be a restriction enzyme recognition site, but simply a place at which cuts can be created with the following conditions (a module-containing assembly vector in a library can be called an "assembly vector" (or "occupied assembly vector") or a "library vector”): a) the cut at 1 in the assembly (library) vector is compatible with a cut which can be created at site 1 in the ORF construction vector family during ORF construct creation; b) the cut at site 6 in the assembly (library) is compatible with a cut which can be created at site 6 in the ORF construction vector family during ORF construct creation; c) in each case, after transfer of the library ORF element to the ORF construction vector, the recognition sites for the Type IIS enzymes chosen for sites 7 & 8 are unique (if present) in the vector product. [0283] For example, the Type IIS enzyme for 7 could be used to cut at site 1 , creating an overhang at 1 which could be used for transfer.
• the construction of a left edge by an equivalent method can be done in the presence of a previously constructed right edge.
• the donor is again a library vector of left-edge type (with site pattern 4-[7-l]-[*-8]-3); and the acceptor now an ORF vector with site pattern l-3-4-[7-*]-6; once again, the donor fragment l-[*-8]-3 replaces the acceptor fragment 1-3.
• assembly vectors are used in which a unique Not I site (4) and a unique Eco Rl site (6) flank the synthon insertion site.
• the module genes each of which is designed so that (a) the module gene contains no Not I or Eco RI sites.
• each module gene in the library is designed with unique Spe I (5) site at the 57amino-terminal edge of the module and a unique Xba I site (2) at the 3 Vcarboxyterminal edge of the module (see Figure 6).
• Type IIS restriction enzymes are used (as described above in Section 4).
• the structure of the module gene-containing assembly vectors in the library can be described as: — — 7—
• 7 will be Bbs I and 8 will be Bsa I.
• the modules are designed so that (a) the module gene contains no Bbs I (7) sites or Bsa I (8) sites as well as being free of Not I (4) sites.
• the generation of cohesive and compatible ends by action of the Type IIS enzymes 7 and 8 requires that a common sequence motif be present at each end of a module and the Type IIS recognition sites be positioned to produce overhangs having the sequence of the common sequence motif.
• restriction sites for Xba I and Spe I positioned at different ends of the module (e.g., as in Figure 6) are used for convenience.
• the common sequence motif is 5'-C T A G-3', the central region of both the Xba I (5 A T ⁇ C T A G A -373 '-A G A T C ⁇ T-5 ') and Spe I sites (5 '-A ⁇ C T A G T-373 '- T G A T C ⁇ A-5 '). Cleavage by Bbs I and Bsa I produces compatible cohesive ends (5'- N N N N C T A G-3').
• the common sequence motif need not be a restriction site (or any particular restriction site) and any number of motifs can be used.
• the assembly vector is digested as for the first module
• assembly vectors in which a unique Not I site (4) and a unique Pac I site (3) flank the synthon insertion site are used to make a library of PKS module genes, each of which is designed so that (a) the module gene contains no Not I or Pac
• the module gene has a unique Spe I (5) site at the 5 '-edge of the module gene and an Xba I site (2) at the 3 '-edge of the module gene.
• module gene-containing assembly vectors in the library can be described as: 4— 15— module— 2 -3— [I]
• a library of such assembly vectors can be described as: - — j5— moduleA— 2 ⁇ — 3- 4—
• module genes can be assembled bidirectionally in a vector. For example, to generate a vector containing genes for modules A-B-C-D-E, the module genes could be individually added to the vector in the order A, B, C, D, E; E, D, C, B, A; C, B, D, E, A; etc.
• the first module gene (A) can be introduced by cutting with Not I (4) and Xba I (2) in the module, and digesting the ORF vector with Not I (4) and Spe I (5) resulting in
• the assembly vector containing module B is digested with Spe I (5) and Pac I (3)
• the ORF vector containing the module A gene is digested with Xba I (2) and Pac I (3), resulting in
• constructs can then be added to construct (V), either next to the module B gene or module A gene.
• constructs can then be added to construct (V), either next to the module B gene or module A gene.
• Constructs (V) - (VIII) can be digested with Spe I (5) and Xba I (2) to remove the 2-5 fragment, producing a gene encoding a polypeptide containing contiguous modules in a single open-reading frame.
• a library can contain incomplete ORFs comprising various combinations of four modules plus accessory units (for example, constructs such as [VI] and [VII] above 1— ⁇ /5— moduleB— 2/5— moduleC— 2— 3— 4— B— moduleD— 2/5— moduleA— 2/5r— 6— [VI] or l—G/5— moduleB— 2/5— moduleD— 2h-3— H5— moduleC— 2/5— moduleA— 2/5 -6— [VII])
• constructs such as [VI] and [VII] above 1— ⁇ /5— moduleB— 2/5— moduleC— 2— 3— 4— B— moduleD— 2/5— moduleA— 2/5r— 6— [VI] or l—G/5— moduleB— 2/5— moduleD— 2h-3— H5— moduleC— 2/5— moduleA— 2/5 -6— [VII]
• the structure of a desired polyketide is assigned a polyketide code (string) by converting the polyketide into a "sawtooth" format (i.e., it is linearized and any post- synthetic modifications are removed) and assigning a one-letter code corresponding to each of the possible 2-carbon ketide units found in polyketides to create a string that describes the polyketide.
• the ketide units of desired polyketide are converted to a module code by determining possible modules that could produce the polyketide.
• the module code is then aligned with those corresponding to known polyketide synthases (preferably by computer implemented scanning of a database of such structures) to identify combinations of modules that function in nature.
• potential sources of module sequences are selected based on the alignment of conceptual modules that could produce the desired polyketide with known PKS modules. Alignments can be ranked by, for example, minimizing non-native inter-module and/or inter-protein interfaces. For example, to synthesize a gene with the structure LD-A-B-C-D-E-F, where LD is a loading domain, and A-E are PKS modules, the alignment might produce in the output shown in Table 6. TABLE 6 HYPOTHETICAL ALIGNMENT OF PKS MODULES
• modules sequences LD A, B-C, D-E-F.
• the junctions A-B and C-D are connected to form a functional PKS.
• Some module sequences may serve the pu ⁇ ose better than others.
• sequences #2 and #3 may both serve as sources of B-C; however, in sequence #2 the native substrate of B is the product of A, and may therefore be more likely to be productive.
• the invention provides libraries of synthetic module genes that contain useful restriction sites at the boundaries of functional domains (see, e.g., Figure 4). Because these sites are common to the entire library, "domain swaps" can be easily accomplished. For example, in module genes having a unique Pst I site at the C-terminus of the KS domain and a unique Kpn I at the C-terminus of the AT domain (see, e.g., Figure 4), the AT domains of these modules can be removed and replaced by different AT domain encoding genes bounded by these sites can be exchanged.
• a library of 150 synthetic module genes each corresponding to a different naturally occurring module gene, can be synthesized, in which each synthetic gene has a unique Spe I restriction site at the 5' end of the gene, an Xba I site at the 3' end of the gene, a Kpn I site at the 3' boundary of each KS domain encoding region, and a Pst I site at the 3' boundary of each AT domain.
• Any of the 150 modules could then be cloned into a common vector, or set of vectors, for analysis, manipulation and expression and, in addition, the presence of common restriction sites allows exchange or substitution of domains or combinations of domains.
• the Kpn I and Pst I sites could be used to exchange domains in any modules having a KS domain followed by an AT domain.
• the invention provides a synthetic gene encoding a polypeptide segment that corresponds to a reference polypeptide segment, where the coding sequence of the synthetic gene is different from that of a naturally occurring gene encoding the reference polypeptide segment.
• the invention provides a synthetic gene encoding a PKS domain that corresponds to a domain of a naturally occurring PKS, where the coding sequence of the synthetic gene is different from that of the gene encoding the naturally occurring PKS.
• Exemplary domains include AT, ACP, KS, KR, DH, ER, MT, and TE.
• the invention provides a synthetic gene encoding at least a portion of a PKS module that corresponds to a portion of a PKS module of a naturally occurring PKS, where the coding sequence of the synthetic gene is different from that of the gene encoding the naturally occurring PKS, and where the portion of a PKS module includes at least two, sometimes at least three, and sometimes at least four PKS domains.
• the invention provides a synthetic gene encoding a PKS module that corresponds to a PKS module of a naturally occurring PKS, where the coding sequence of the synthetic gene is different from that of the gene encoding the naturally occurring PKS.
• the polypeptide segment encoded by the synthetic gene corresponds to at least about 20, at least about 30, at least about 50 or at least about 100 contiguous amino acid residues encoded by the naturally occurring gene
• the amino acid sequences of individual domains, linkers, combinations of domains, and entire modules can be based on (i.e., "correspond to") the sequences of known (e.g., naturally occurring) domains, combinations of domains, and modules.
• a first amino acid sequence e.g., encoding at least one, at least two, at least three, at least four, at least five or at least six PKS domains selected from AT, ACP, KS, KR, DH, and ER
• the naturally occurring domains, linkers, combinations of domains, and modules are from one of erythromycin PKS, megalomicin PKS, oleandomycin PKS, pikromycin PKS, niddamycin PKS, spiramycin PKS, tylosin PKS, geldanamycin PKS, pimaricin PKS, pte PKS, avermectin PKS, oligomycin PSK, nystatin PKS, or amphotericin PKS.
• two amino acids sequences are substantially the same when they are at least about 90% identical, preferably at least about 95% identical, even more preferably at least about 97% identical, and sometimes at least about 98% or at least about 99% identical. Sequence identity between two amino acid sequences can be determined by optimizing residue matches by introducing gaps if necessary.
• One of several useful comparison algorithms is BLAST; see Altschul et al., 1990, "Basic local alignment search tool.” J. Mol. Biol. 215:403-410; Gish et al., 1993, "Identification of protein coding regions by database similarity search.” Nature Genet.
• the invention provides a synthetic gene that encodes one or more PKS modules (e.g., a sequence encoding an AT, ACP and KS activity, and optionally one or more of a KR, DH and ER activity).
• PKS modules e.g., a sequence encoding an AT, ACP and KS activity, and optionally one or more of a KR, DH and ER activity.
• the synthetic gene has at most one copy per module-encoding sequence of a restriction enzyme recognition site such as Spe I, Mfe I, Afi II, Bsi WI, Sac II, Ngo MIV, Nhe I, Kpn I, Msc I, Bgl II, Bss HII, Sac II, Age I, Pst I, Kas I, Mlu I, Xba I, Sph I, Bsp E, and Ngo MIN recognition sites.
• a restriction enzyme recognition site such as Spe I, Mfe I, Afi II, Bsi WI, Sac II, Ngo MIV, Nhe I, Kpn I, Msc I, Bgl II, Bss HII, Sac II, Age I, Pst I, Kas I, Mlu I, Xba I, Sph I, Bsp E, and Ngo MIN recognition sites.
• the invention provides a synthetic gene encoding a PKS module having a Spe I site near the sequence encoding the amino-terminus of the module-encoding sequence; and/or b) a Mfe I site near the sequence encoding the amino-terminus of a KS domain; and/or c) a Kpn I site near the sequence encoding the carboxy-terminus of a KS domain; and/or d) a Msc I site near the sequence encoding the amino-terminus of an AT domain; and/or e) a Pst I site near the sequence encoding the carboxy-terminus of an AT domain; and/or f) a BsrB I site near the sequence encoding the amino-terminus of an ER domain; and/or g) an Age I site near the sequence encoding the amino-terminus of a KR domain; and/or h) an Xba I site near the sequence encoding the amino-terminus of an ACP domain.
• the invention provides a vector (e.g., an expression vector) comprising a synthetic gene of the invention.
• a vector that comprises sequence encoding a first PKS module and one or more of (a) a PKS extension module; (b) a PKS loading module; (c) a thioesterase domain; and (d) an inte ⁇ olypeptide linker. Exemplary vectors are described in Section 7, above.
• the invention provides a cell comprising a synthetic gene or vector of the invention, or comprising a polypeptide encoded by such a vector.
• the invention provides a cell containing a functional polyketide synthase at least a portion of which is encoded by the synthetic gene.
• a functional polyketide synthase at least a portion of which is encoded by the synthetic gene.
• Such cells can be used, for example, to produce a polyketide by culture or fermentation.
• Exemplary useful expression systems e.g., bacterial and fungal cells are described in Section 3, above.
• the invention provides a large variety of vectors useful for the methods of the invention (including, for example, stitching methods described in Section 4 and analysis using multimodule constructs as described in Section 7).
• the invention provides a cloning vector comprising, in the order shown, (a) SM4 - SIS - SM2 - Ri or (b) L - SIS - SM2 - Ri (where SIS is a synthon insertion site, SM2 is a sequence encoding a first selectable marker, SM4 is a sequence encoding a second selectable marker different from the first, Ri is a recognition site for a restriction enzyme, and L is a recognition site for a different restriction enzyme).
• the selectable marker is a gene conferring drug resistance.
• the invention provides a vector comprising SM4 - 2S ⁇ - Syi - 2S 2 - SM2 - Ri, where 2Sj is a recognition sites for first Type IIS restriction enzyme, 2S 2 is a recognition sites for a different Type IIS restriction enzyme, and Sy is synthon coding region.
• the invention provides a vector comprising L - 2S] - Sy 2 - 2S 2 - SM2 - Ri.
• Sy encodes a polypeptide segment of a polyketide synthase.
• Bbs I and/or Bsa I are used as the Type IIS restriction enzymes.
• the invention provides a composition containing such a vector and a Type IIS restriction enzyme that recognizes either 2S ⁇ or 2S 2 .
• the invention provides a kit containing a vector and a type IIS restriction enzyme that recognizes 2Sj or 2S 2> (or a first type IIS restriction enzyme that recognizes 2Sj and a second type IIS restriction enzyme that recognizes 2S 2 ).
• the invention provides a composition containing a cognate pair of vectors.
• a cognate pair means a pair of vectors that can be used in combination to practice a stitching method of the invention.
• the composition contains a vector comprising SM4-2S ⁇ -Sy ⁇ -2S 2 -SM2-R ⁇ digested with a Type IIS restriction enzyme that recognizes 2S 2 , and a vector comprising SM5-2S 3 -Sy 2 -2S 4 - SM3-R] digested with a Type IIS restriction enzyme that recognizes 2Sj .
• the composition contains a vector comprising L-2S ⁇ -Sy ⁇ -2S 2 -SM2-R ⁇ digested with a Type IIS restriction enzyme that recognizes 2S 2 , and a vector comprising L'— 2S ⁇ -Sy 2 - 2S 2 -SM3-R ⁇ digested with a Type IIS restriction enzyme that recognizes 2S].
• the invention provides a vector containing a first selectable marker, a restriction site (Ri) recognized by a first restriction enzyme, a synthon coding region flanked by a restriction site recognized by a first Type IIS restriction enzyme and a restriction site recognized by a second Type IIS restriction enzyme, where digestion of the vector with the first restriction enzyme and the first Type IIS restriction enzyme produces a fragment containing the first selectable marker and the synthon coding region, and digestion of the vector with the first restriction enzyme and the second Type IIS restriction enzyme produces a fragment containing the synthon coding region,
• the vector has a second selectable marker and digestion of the vector with the first restriction enzyme and the first Type IIS restriction enzyme produces a fragment containing the first selectable marker and the synthon coding region, and not containing the second selectable marker, and digestion of the vector with the first restriction enzyme and the second Type IIS restriction enzyme produces a fragment comprising the second selectable marker and the synthon coding region, and not containing the first selectable marker.
• the vector can contain a third selectable marker.
• the invention provides vectors, vector pairs, primers and/or enzymes useful for the methods disclosed herein, in kit form.
• the kit includes a vector pair described above, and optionally restriction enzymes (e.g., Type IIS enzymes) for use in a stitching method.
• a library contains a plurality of genes (e.g., at least about 10, more often at least about 100, preferably at least about 500, and even more preferably at least about 1000) encoding modules that correspond to modules of naturally occurring PKSs, where the modules are from more than one naturally occurring PKS, usually three or more, often ten or more, and sometimes 15 or more.
• a library contains genes encoding domains that correspond to domains from more than one polyketide synthase protein, usually three or more, often ten or more, and sometimes 15 or more.
• a library contains genes encoding domains that correspond to domains from more than one polyketide synthase module, usually fifty or more, and sometimes 100 or more.
• the members of the library have shared characteristics, e.g., shared structural or functional characteristics.
• the shared structural characteristics are shared restriction sites, e.g., shared restriction sites that are rare or unique in genes or in designated functional domains of genes.
• a library of the invention contains genes each of which encodes a PKS module, where the module-encoding regions of the genes share at least three unique restriction sites (for example, Spe I, Mfe I, Aft II, Bsi WI, Sac II, Ngo MIV, Nhe I, Kpn I, Msc I, Bgl II, Bss HII, Sac II, Age I, Pst I, Bsr Bl, Kas I, Mlu I, Xba I, Sph I, Bsp E, and Ngo MIV recognition sites).
• a library of the invention contains genes that encode more than one PKS module each, where each module-encoding region shares at least three unique restriction sites.
• the number of shared restriction sites is more than 4, more than 5 or more than 6.
• Exemplary sites and locations of shared restriction sites include a) a Spe I site near the sequence encoding the amino-terminus of the module- encoding sequence; and/or b) a Mfe I site near the sequence encoding the amino-terminus of a KS domain; and/or c) a Kpn I site near the sequence encoding the carboxy-terminus of a KS domain; and/or d) a Msc I site near the sequence encoding the amino-terminus of an AT domain; and/or e) a Pst I site near the sequence encoding the carboxy-terminus of an AT domain; and/or f) a BsrB I site near the sequence encoding the amino-terminus of an ER domain; and/or g) an Age I site near the sequence encoding the amino-terminus of a KR domain; and/or h) an Xba I site near the sequence
• genes of the library are contained in cloning or expression vectors.
• the PKS module-encoding genes in a library also have in-frame coding sequence for an additional functional domain, such as one or more PKS extension modules, a PKS loading module, a thioesterase domain, or an inte ⁇ olypeptide linker.
• the invention provides a computer readable medium having stored sequence information.
• the computer readable medium may include, for example, a floppy disc, a hard drive, random access memory (RAM), read only memory (ROM), CD-ROM, magnetic tape, and the like.
• a data signal embodied in a carrier wave (e.g., in a network including the Internet) may be the computer readable storage medium.
• the stored sequence information may be, for example, (a) DNA sequences of synthetic genes of the invention or encoded polynucleotides, (b) sequences of oligonucleotides useful for assembly of polynucleotides of the invention, (c) restriction maps for synthetic genes of the invention.
• the synthetic genes encode PKS domains or modules.
• the invention provides an automated system 10 comprising a liquid handler 12 (e.g., Biomek FX liquid handler; Beckman-Coulter), and a random access hotel 14 (e.g., CytomatTM Hotel; Kendro) coupled to the liquid handler 12.
• Liquid handler 12 includes a plurality of positions PI through PI 9 which can accept microplates and other vessels used in system 10. As discussed below and as shown in Figure 19, a number of the positions include additional functionality.
• the random access hotel 14 is capable of storage of one or more source microplates 16 each carrying oligonucleotide solutions one or more PCR plates 18 comprising synthon assembly wells, and one or more (optional) sources 20 of LIC extension primers (e.g., uracil-containing oligonucleotides), and is capable of delivery of plates and pipette tips to liquid handler 12.
• the hotel contains > 5, > 10, or > 20 microplates (and, for example >50, >100, or >200 different oligonucleotide solutions).
• source 20 includes a micro-centrifuge tube. Source 20 could also be a vial or any other suitable vessel.
• Random access hotel 14 is used for primer mixing, PCR-related procedures, sequencing and other procedures.
• liquid handler 12 comprises a deck 21 with heating element 22 at position P4 and cooling element 23 at position PI 2.
• Deck 21 can also include an automatic reading device 24, such as a bar code reader, located at position P7 in the example of Figure 19.
• System 10 also includes a thermal cycler 26, a plate reader 28, a plate sealer 31 and a plate piercer 30.
• the reading device 24 is capable of tracking data, and enables hit picking for library compression and expansion as discussed in section 6 above. Hit picking can be useful, for example, for rearranging clones from a library according to user input.
• Random access hotel 32 provides plate storage needed for high-throughput primer (oligonucleotide) mixing, and decreases user intervention during plasmid preparations and sequencing.
• Plate reader 28 includes a spectrophotometer for measuring DNA concentration of samples. Data taken from plate reader 28 is used to normalize DNA concentrations prior to sequencing.
• Thermal cycler 26 serves as a variable temperature incubator for the PCR steps necessary for gene synthesis.
• the reading device 24 is integrated for sample tracking.
• System 10 also includes robotic arm 40 for transporting sample and plates between different elements in system 10 such as between liquid handler 12 and random access hotel 14. [0331] For illustration and not as any limitation, synthesis can be automated in the following fashion:
• Robotic arm 40 is coupled to the liquid handler 12 and transports one or more source microplates and PCR plates from random access hotel 14 to liquid handler 12.
• Liquid handler 12 dispenses appropriate amounts of each of about 25 oligonucleotides from source microplates 16 into a "synthon assembly" well of a PCR plate 18 such that each well contains equimolar amounts of the primers necessary to make a synthon. Since each primer mix contains a different primers (oligonucleotides), as described above, a spreadsheet program is optionally utilized to identify the primer and automatically extract the data necessary for liquid handler 12 to determine which primers correspond to which synthon assembly well.
• LIC extensions containing uracil are added by liquid handler 12 to the PCR products (amplicons) by a second PCR step.
• the primers containing LIC extensions are added (LIC extension mixture) to each well to prepare the "linkered- synthon.”
• a synthon cloning mixture is prepared by combining the linkered synthon and a synthon assembly vector in liquid handler 12. Each synthon cloning mixture is then transferred to a sister plate containing competent E. coli cells for transformation, which are positioned at cooling element 12. After transformation, cells in each well are spread on petri dishes, which are incubated to form isolated colonies.
• the plates are transferred by robot arm 40 from an incubator 54 to an automated colony picker 50 (e.g., Mantis; Gene
• Liquid growth medium is used to prepare DNA for sequencing, e.g., as described above.
• the liquid handler 12 then sets up sequencing reactions using primers in both directions. Sequencing is carried out using an automated sequencer (e.g., ABI 3730 DNA sequencer).
• a bottleneck in the gene synthesis efforts can be the analysis of DNA sequencing data from synthons. For example, sequence analysis of a single synthon may require sequencing 5 clones in both directions.
• a typical PKS gene might involve analysis of 100 synthons, with 5-forward and 5-reverse sequences each (1000 total sequences).
• a sequence of a synthetic gene wherein the synthetic gene is divided into a plurality of synthons, sequences of synthon clones wherein each synthon of the plurality of synthons is cloned in a vector, a sequence of the vector without an insert is entered in the program 1912.
• DNA sequencer trace data tracing each synthon sequence to a particular clone are also provided 1912.
• the nucleotide sequence is analyzed (by base calling) 1910 for each cloned sample and vector sequences that occur in the sample sequence are eliminated 1920.
• a base-calling program such as PHRED is used to estimate a probability of error for each base-call, as a function of certain parameters computed from the trace data.
• a map depicting the relative order of a linked library of overlapping synthon clones representing a complete synthetic gene segment is constructed ("contig map") 1930 and the contig sequences are aligned against the reference sequence of the synthetic gene 1940.
• the program identifies errors and alignment scores for each sample 1950 and generates a comprehensive report indicating ranking of samples, substitution-insertion-deletion errors, most likely candidate for selection or repair 1960.
• PHRED After calling bases, PHRED writes the sequences to files in either FASTA format, the format suitable for XBAP, PHD format, or the SCF format. Quality values for the bases are written to FASTA format files or PHD files, which can be used by the PHRAP sequence assembly program in order to increase the accuracy of the assembled sequence.
• Racoon consolidates the forward and reverse sequences of each clone, and sends the composite to PHRAP for alignment with others from the same synthon.
• the software calls out the correct sequences, and identifies and tabulates the position, type (insertion, deletion, substitution) and number of errors in all clones. It also detects silent mutations, amino acid changes, unwanted restriction sites and other parameters that can disqualify the sample. The user then decides how to use the data (error analysis, statistics, etc.).
• Rhoon The features of Racoon include: (i) reading multiple data formats (SCF, ABI, ESD); (ii) performing base calling, alignments, vector sequence removal and assemblies; (iii) high throughput capability for analysis for multiple 96 well plate samples; (iv) detecting insertions, deletions and substitutions per sample, and silent mutations; (v) detecting unwanted restriction sites created by silent mutations; (vi) generating statistical reports for sample sets which results can be downloaded or stored to a database for further analysis.
• the Racoon system is implemented using the following software components: Phred, Phrap, Cross Match (Ewing B, Hillier L, Wendl M, Green P: Base calling of automated sequencer traces using phred. I. Accuracy assessment.
• Genome Research 8, 175- 185 (1998); Ewing B, Green P: Basecalling of automated sequencer traces using phred. II. Error probabilities. Genome Research 8, 186-194 (1998); Gordon, D., C. Desmarais, and P. Green. 2001. Automated Finishing with Autofinish. Genome Research. 11(4):614-625); Python 2.2 as integration and scripting language (Python Essential Reference, Second Edition by David M. Beazley); GeMS Application Programming Interface (Kosan proprietary software); Apache Web Server version 2.0.44 (http://httpd.apache.org); and Red Hat Linux Operating System version 8.0 (http://www.redhat.com).
• Step I Data population.
• the user inputs into the Racoon program raw sequencing data, vector sequence, and a look-up table that maps the sample to a specific synthon.
• the program creates run folders for each sample and correctly puts the sequencing files (forward and reverse directions) in its folder, along with the desired synthon sequence.
• the program uses the look-up table to find the related synthon sequence from a database containing the synthetic gene design data.
• Step II Base calling, vector screening and sequence assembly. Multiple reads can be analyzed using base-calling software such as PHRED and PHRAP (see, e.g., Ewing and Green (1998) Genome Research 8:175-185; Ewing and Green (1998) Genome Research 8:186-194; and Gordon et al. (1998) Genome Research. 8:195-202) to obtain a certainty value for each sequenced nucleotide.
• base-calling software such as PHRED and PHRAP (see, e.g., Ewing and Green (1998) Genome Research 8:175-185; Ewing and Green (1998) Genome Research 8:186-194; and Gordon et al. (1998) Genome Research. 8:195-202) to obtain a certainty value for each sequenced nucleotide.
• a python script is executed on each sample folder containing the chromatogram files for a particular synthon. This script in turn executes the following programs in succession:
• PHRED a base calling software to determine the nucleotide sequence on the basis of multi-color peaks in the sequence trace.
• PHRED is a publicly available computer program that reads DNA sequencer trace data, calls bases, assigns quality values to the bases, and writes the base calls and quality values to output files (see, for example, Ewing and Green, Genome Research 8:186-194 (1998). After calling bases, PHRED writes the sequences to files in either FASTA format, the format suitable for XBAP, PHD format, or the SCF format.
• CROSS MATCH an implementation of the Smith- Waterman sequence alignment algorithm. It is used in this step to remove the vector sequence from each sample.
• PHRAP a package of programs for assembling shotgun DNA sequence data. It is used to construct a contig sequence as a mosaic of the highest quality parts of reads. The resulting assembly files are candidates for comparison and analysis.
• Step III Error detection, ranking of samples. A python script reruns CROSSJVIATCH with the pu ⁇ ose of determining variation between the original synthon sequence and the resulting assembly files for each sample.
• Each synthon folder has a collection of sample folders and the associated files generated by PHRED, PHRAP and CROSS_MATCH.
• a python program detects each of the related samples and associates them with a synthon. It looks for the required information from the output files and ranks the samples. The program looks for silent mutations; checks freshly introduced restriction sites; and generates a report that can be used for further analysis.
• Rhoon is capable of processing large datasets rapidly. About 200 samples can be analyzed in less than 2 minutes. This included the base calling, vector screening, detection of errors and generation of reports. The results can be saved as HTML files or the individual sample runs can be downloaded to the desktop for further analysis.
• the assembly of synthetic DNA fragments is adapted from a previously developed procedure (Stemmer et al., 1995, Gene 164:49-53; Hoover and Lubkowski, 2002, Nucleic Acids Res. 30:43).
• the gene synthesis method uses 40-mer oligonucleotides for both strands of the entire fragment that overlap each other by 20 nucleotides.
• Equal volumes of overlapping oligonucleotides for a synthon are added together and diluted with water to a final concentration of 25 ⁇ M (total). The oligo mix is assembled by PCR.
• the PCR mix for assembly is 0.5 ⁇ l Expand High Fidelity Polymerase (5 units/ ⁇ L, Roche), 1.0 ⁇ l 10 mM dNTPs, 5.0 ⁇ l 10 x PCR buffer, 3.0 ⁇ l 25 mM MgCl 2 , 2.0 ⁇ l 25 ⁇ M Oligo mix, 38.5 ⁇ l water.
• the PCR conditions for assembly begins with a 5 minute denaturing step at 95 °C, followed by 20-25 cycles of denaturing 95°C at 30 seconds, annealing at 50 or 58°C for 30 seconds, and extension temperature 72°C for 90 seconds.
• Amplification Amplification
• the reaction mix for the amplification PCR is 0.5 ⁇ l Expand High Fidelity Polymerase, 1.0 ⁇ l 10 mM dNTPs, 5.0 ⁇ l 10 x PCR buffer, 3.0 ⁇ l 25 mM MgC12 (1.5mM), 1.0 ⁇ l 50 ⁇ M stock of forward Oligo, 1.0 ⁇ l 50 ⁇ M stock of reverse Oligo, 1.25 ⁇ l of assembly round PCR sample (template), and 37.25 ⁇ l water
• the program for amplification includes an initial denaturing step of 5 minutes at 95°C. Twenty-five cycles of 30 seconds of denaturing at 95°C, annealing at 62°C for 30 seconds, and extension at 72°C of 60 seconds, with a final extension of 10 minutes.
• amplification of samples is verified by gel electrophoresis. If the desired size is produced, the sample is cloned into a UDG cloning vector.
• a second round of assembly is performed using a PCR mix for assembly of 16 ⁇ L first round assembly 0.5 ⁇ L Expand High Fidelity polymerase, 1.0 ⁇ L lOmM dNTPs, 3.3 ⁇ L 10 x PCR buffer, 2.0 ⁇ L 25 mm MgCl 2 , 2.0 ⁇ L oligo mix, and 35.2 ⁇ L water.
• the PCR conditions for the second assembly are the same as the first assembly described above. After the second assembly an amplification PCR is performed.
• Vector preparation To prepare vectors for UDG-LIC, 10 ⁇ L of vector (1-2 ⁇ g) is digested with 1 ⁇ L Sac I (20 units/ ⁇ L) at 37°C for 2 h. 1 ⁇ L of nicking endonuclease N. BbvC IA (10 units/ ⁇ L) is added and the sample is incubated an additional two hours at 37°C. The enzymes are heat inactivated by incubation at 65°C for 20 minutes, and then a MicroSpin G-25 Sephadex column (Amersham Biosciences) is used to exchange the digestion buffer for water.
• the samples are treated with 200 units of Exonuclease III (Trevigen) for 10 minutes at 30°C and purified on a Qiagen quik column, eluting to a final volume of 30 ⁇ L. Samples are checked for degradation by gel electrophoresis and used for test UDG-cloning reaction to determine efficiency of cloning.
• Tevigen Exonuclease III
• UDG cloning of fragments To clone the synthetic gene fragments, they are treated with UDG in the presence of the LIC vector. 2 ⁇ L of PCR product (10 ng) is digested for 30 minutes at 37°C with 1 ⁇ L (2 units) of UDG (NEB) in the presence of 4 ⁇ L of pre-treated dU vector (50 ng) in a final reaction volume of 10 ⁇ L. [0362] The resulting mixtures are placed on ice for 2 minutes, and the entire reaction volume (lO ⁇ L) is transformed into DH5 ⁇ E. coli cells, and selected on LB plates with 100 ⁇ g/mL carbenicillin (i.e., SMI). The plasmids are purified for characterization and subsequent cloning steps. Endonuclease VIII method
• Vector Preparation The vector is linearized by digestion with Sac I. Nicking endonuclease (100 units N. BbvC IA) is added and the mixture incubated at 37°C for 2 h. DNA is isolated from the reaction mixture by phenol/chloroform extraction followed by ethanol precipitation.
• UDG Cloning 20 ng linearized vector, 10 ng PCR product, and 1 unit USER enzyme (a mixture of endonuclease VIII and UDG available as a kit from New England Biolabs) are combined and incubated 15 m at 37°C, 15 m at room temperature, and 2 m on ice, and used to transform E coli DH5 ⁇ . Endonuclease VIII is described in Melamede et al., 1994, Biochemistry 33:1255-64.
• EXAMPLE 3 CHARACTERIZATION AND CORRECTION OF CLONED SYNTHONS
• Identification of clones To identify clones containing the correct PCR product (e.g. not having sequence errors), plasmid DNA is isolated from several (typically five or more) clones and sequenced. Any suitable sequencing method can be used. In one embodiment, sequencing is carried out using DNA obtained by rolling circle amplification (RCA), using phi29 DNA polymerase (e.g., Templicase; Amersham Biosciences). See, Nelson et al, 2002, "TempliPhi, phi29 DNA polymerase based rolling circle amplification of templates for DNA sequencing" Biotechniques Suppl:44-7. In one embodiment, each colony containing a plasmid to be sequenced is suspended in 1.4 mL LB medium and 1 I is used in the amplification/sequencing reaction.
• RCA rolling circle amplification
• phi29 DNA polymerase e.g., Temp
• Sequence analysis After sequencing, the results can be aligned and compared to the intended sequence. Preferably this process is automated using a RACOON program (described below) to identify the correct sequences after aligning the sequences corresponding to each synthon.
• Clones of interest can be stored in a variety of ways for retrieval and use, including the Storage IsoCode® IDTM DNA library card (Schleicher & Schuell BioScience).
• SDM site-directed mutagenesis
• PCR-based site-directed mutagenesis using the 40-mer oligonucleotides used in the original gene synthesis.
• a sample with only one point mutation from the desired target sequence was corrected as follows: The overlapping oligonucleotides from the assembly of the synthons that corresponded to that part of the synthon were identified and used for the correction of the synthon.
• the error-containing sample DNA was amplified using a Pfu based PCR method using overlapping oligonucleotides (nos. 1 and 2) that cover the area of the mutation (see Fischer and Pei, 1997, "Modification of a PCR-based site directed mutagenesis method” Biotechniques 23:570-74).
• the reaction mixture included DNA template [5-20 ng], 5.0 ⁇ L; 10 x Pfu buffer, 0.5 ⁇ L; Oligo #1 [25 ⁇ M], 0.5 ⁇ L; Oligo #2 [25 ⁇ M], 1.0 ⁇ L; 1 OmM dNTPs, 1.0 ⁇ L; Pfu DNA polymerase, and sterile water to 50 ⁇ L.
• PCR conditions were as follows: 95°C 30 seconds (2 minutes if using Pfu with heat sensitive ligand), 12-18 cycles of: 95°C 30 seconds, 55°C 1 minutes, 68°C 2 minutes/kb plasmid length (1 min kb if Pfu Turbo).
• the methylated (parental) DNA was degraded by adding 1 ⁇ L Dpn I (10 units) to the PCR reaction and incubating 1 hr at 37°C. The resulting sample was transformed into competent DH5 ⁇ cells. Plasmid DNA from four clones was isolated and sequenced to identify desired clones.
• the first set of sites are those located at the edge of domains (including the Xba I and Spe I sites at the edges of modules).
• the second set of sites could be located at synthon edges, but were not generally found at domain edges.
• restriction sites described in this example are exemplary only, and that additional and different sites can be identified by the methods of disclosed herein, and used in the synthetic methods of the invention.
• PKS gene clusters were aligned (see Table 9). Then, regions of high homology near edges of domains that, when reverse translated to all possible DNA sequences, revealed a 6-base or greater restriction site were identified. In specified cases, a conservative change of the amino acid in order to place the restriction site was allowed, provided that change was found in many of the PKS modules. In a few cases, restriction sites were placed in putative inter- domain sequences that required change of amino acids. In such cases there was experimental evidence that the modified amino acid sequence did not disturb functionality in some PKSs.
• amino acid and nucleotide sequence used for reference begins at the first residue of the EPIAIV found on the N-terminal edge of the KS domain; homologous motifs are found at the N-terminal edges of all 140 KS domains in the sample.
• An Mfe I site can be inco ⁇ orated near the left edge of the KS coding sequence using bases 2-7 of the 9 bases coding for the tripeptides homologous to the PIN of the initial motif of the KS. 70% of the 140 KSs need no change in amino acids; the remaining 30%o require only conservative changes [81% N->I, 17% L->I and 2% M to I]. On the right edge of 100%) of the 140 KS domains, there is a conserved GT (nt 1267 - 1272) that can be encoded by the sequence for a Kpn I restriction site.
• An Msc I site can be inco ⁇ orated near the left edge of the AT coding sequence (nt 1590-1595) at the site of the GQ dipeptide found in 100% of the sampled ATs.
• a Pst I site was placed at the right side of the AT (nt 2611 - 2617) at a position where Pst I and Xho I had been previously placed without loss of functionality after domain swaps.
• This variable sequence region is identified in many modules by a Y-x-F-x-x-x-R-x-W motif where "x" is any amino acid; in others, alignments always produce a well-defined equivalent position. The two amino acids to the immediate right (C-terminal to W ) of this motif are modified to introduce the Pst I site.
• an Age I site can be placed at the TG dipeptide (nt 4894 - 5542) found in 100% of the 136 KRs in the test sequences.
• a Bsr Bl site can be placed at its left edge, which codes for the conserved PL dipeptide (nt 4072 - 4929) found in all but one of the 17 ERs in the test sequences (the remaining ER is the only ER domain in the sample without activity). Since the ER and KS domains are separated by only 4 to 6 amino acids, the Age I site of the KR serves as the other excision site for the ER.
• This site is analogous to that described for the Xba I, above (normally positions 41 and 42 after the active site serine), and is followed by the intermodular linker to the Mfel site in the KS.
• the Spe I to Mfel linker sequence is not needed, and the segment of the module synthesized consists of only the Mfel-Xba I body.
• the present invention provides, ter alia, a method for identifying restriction enzyme recognition sites useful for design of synthetic genes by (i) obtaining amino acid sequences for a plurality of functionally related polypeptide segments; (ii) reverse-translating said amino acid sequences to produce multiple polypeptide segment-encoding nucleic acid sequences for each polypeptide segment; (iii) identifying restriction enzyme recognition sites that are found in at least one polypeptide segment-encoding nucleic acid sequence of at least about 50% of the polypeptide segments.
• Preferred restriction enzyme recognition sites are found in at least one polypeptide segment- encoding nucleic acid sequence of at least about 75% of the polypeptide segments, even more preferably at least about 80%, even more preferably at least about 85%, even more preferably at least about 90%, even more preferably at least about 95%, and sometimes about 100%).
• Examples of functionally related polypeptide segments include polyketide synthase and NRPS modules, domains, and linkers.
• the functionally related polypeptide segments are regions of high homology in PKS modules or domains (i.e., rather than the entire extent of a module or domain).
• the invention also provides a method of making a synthetic gene encoding a polypeptide segment by (i) identifying one, two three or more than three restriction sites as described above, and (ii) producing a synthetic gene encoding the polypeptide segment that differs from the naturally occurring gene by the presence of the restriction site(s) and (iii) optionally differs from the naturally occurring gene by the removal of the restriction site(s) from other regions of the polypeptide segment encoding sequence.
• each site #1 can be joined to site # 11 of a second module (or an equivalent Xba I from another upstream unit); and each #11 to a Spe I.
• #1/#11 in the final construct is only a single location, coding for the dipeptide SerSer (this location has previously been successfully used in cases where the native amino acids were replaced with the homologous dipeptide ThrSer). No amino acid changes are required in sites other than #la, #7 and #1/#11. At each of these three sites, a history of previous successful exchanges is available.
• the invention provides a PKS polypeptide having a non-natural amino sequence, comprising a KS domain comprising the dipeptide Leu-Gin at the carboxy- terminal edge of the domain; and/or an ACP domain comprising the dipeptide Ser-Ser at the carboxy-terminal edge of the domain.
• a list of restriction enzymes is provided, such that the stated number of cases for each site (see Table 9) one of the list is compatible with the amino acid sequence.
• constructs are designed by using one restriction site for the 5' synthon, and a second with compatible overhang for the 3' synthon.
• sequences of domains, modules and ORFs of PKSs and PKS-like polypeptides can be obtained from public databases (e.g., GenBank) and include, for illustration and not limitation, accession numbers sp
• Epothilone U.S. Pat. No. 6,303,342
• Erythromycin WO 93/13663; U.S. Pat. No. 5,824,513; Donadio et al., 1991, Science 252:675-79; Cortes et al., 1990, Nature 348:176-8
• FK-506 Motamedi et al., 1998, Eur. J. Biochem. 256:528-34; Motamedi et al., 1997, Eur. J. Biochem. 244:74-80
• FK- 520 U.S. Pat. No. 6,503,737; see also Nielsen et al., 1991, Biochem.
• Lovastatin U.S. Pat. No. 5,744,350
• Nemadectin MacNeil et al., 1993, supra
• Niddamycin Kakavas et al., 1997, J. Bacteriol. 179:7515-22
• Oleandomycin Swan et al., 1994, Mol. Gen. Genet. 242:358-62; U.S. Pat. No. 6,388,099; Olano et al., 1998, Mol. Gen. Genet. 259:299-308)
• Platenolide EP Pat. App. 791,656
• Rapamycin Rapamycin (Schwecke et al., 1995, Proc. Natl. Acad. Sci.
• the modification comprises replacing a codon in the synthetic gene that encodes an amino acid not found at that position in the naturally- occurring protein with a codon that encodes the amino acid found at that position in the naturally-occurring protein.
• Modification can be by any number of methods, including by point mutation of the synthetic gene and by re-synthesis of portions of the gene (e.g., using oligomers, synthons, and multisynthons prepared during the initial synthesis).
• DEBS Module 2 is a 4344 bp module. The module was designed to give 10 synthons of varying length (range, 350-700 bp). Each of the synthons was prepared, and the composite results are provided in Table 13. The ten synthons of DEBS Module2 were assembled by conventional methods (e.g., 3-way ligations) into a single module and secondary sequencing was performed to verify the presence of the desired sequence. Synthons for which the correct sequence was not obtained the first attempt were used for optimization and error determination and the numbers in parenthesis in Table 13 represent the second set of results.
• EXAMPLE 6 EXPRESSION OF SYNTHETIC DEBS MOD2 IN E. COLI
• the DEBS Mod2 gene in an E. coli strain having high 15-Me-6dEB production was replaced with a synthetic version (Example 5) and protein expression and polyketide titer were compared.
• the strain employed expresses a DEBS Mod2 derivative (with the KS5 N-terminal linker) from a stable RSFlOlO-based vector and DEBS2&3 from a single pET vector.
• the background strain (K207-3) has genes required for pantetheinylation and CoA thioester synthesis integrated on the chromosome. T7 promoters control Mod2 and DEBS 2&3 expression.
• the Ndel-EcoRI fragment of this plasmid (pKOS378-014) containing the Mod2 ORF was inserted into an pRSFlOlO backbone to create the expression vector pKOS378-030.
• the E. coli host strain used was K207-3, which has sfp, prpE, pccB, and accAl genes for ACP pantetheinylation and CO-A thioester synthesis integrated on its chromosome.
• the protein sequences of the synthetic and WT Mod2 constructions are identical except for 4 substitutions in the synthetic gene required for restriction site engineering (L914Q, G1467S, T1468S, and P1551G)
• Module 001 (DEBSmodule2) was used for initial testing of gene synthesis and therefore the error rate (avg of ⁇ 6.5 errors/kb) was higher for these synthons.
• Module 2 was prepared as described in Example 5. The multi-synthon components of the remaining modules were then stitched together and selected according to the strategy shown in Figure 16 and Figure 17.
• DEBS2 was resequenced and it was determined that the GenBank sequence had five incorrect nucleotide bases (point errors); the correction to the nucleotide sequence resulted in replacement of three amino acids.
• DEBS3 was resequenced and it was determined that the GenBank sequence had seven incorrect bases (point errors) as well as a sequence error that resulted in replacement of 2 base pairs with 5 base pairs; the result was addition a correction at three amino acid position as well as replacement of a fourth amino acid with a pair of new residues.
• the DEBSl synthetic gene differed from M63676 sequence (as corrected in note la and lb, above) at 9 positions. These changes introduce in the module one or more of: a Spel site, an Xbal site (resulting in a Spel/Xbal site encoding SerSer); a Pstl site (resulting in ProGlu); a Mfel site (L, V, M - I).
• the addition of the 3-prime sequence GGGAATTCT (resulting in GlyAsnSer) to facilitate addition of tags is not included in the calculation.
• the cmyc-AlexaFluor488 antibody provides a very accurate range of quantitation in the 50-1000 ng range.
• the FLAG-Cy5 antibody is accurate across a range of 50-500 ng, and clearly suffers from signal saturation at the 1000 ng level.
• the ratios of the peak areas are also stable across the 10-500 ng range, allowing for detection of N-terminal or C-terminal degradation, as well as stoichiometric analysis of protein levels.
• DEBS module 2 HA flag, brs, his HA-mod2-flag-brs-his DEBS module 2 c-myc, flag, brs, his cmyc-mod2-fiag-brs-his DEBS module 2HA, his mod2-HA-his DEBS2 c-myc, his DEBS2-c-myc-his
• a synthetic DEBS module 2 protein (mod2) was expressed in E. coli K-207-3 as a fusion protein (c-myc-mod2-flag-brs-his). Cloning of the module 2 gene into an expression vector in frame with genes encoding the tag sequences was facilitated by inclusion of an Eco RI site in the synthetic gene. DEBS module2 with N- and C-terminal epitope tags was co-expressed with DEBS2 and DEBS3 in an E. coli k-207-3. At 20 and 40 hours, samples from production cultures were subjected to SDS-PAGE (two colonies of each strain were tested).
• Gels were either stained with sypro red or subjected to Western blotting, using fluorescently-labeled antibodies directed against the epitope tags, c-myc, flag and biotin. Monoclonal antibodies were labeled with fluorescent dyes (alexa 488 and alexa 647) such that two fluorescent signals could be monitored simultaneously.
• the modular structure (domain organization) of the epothilone polyketide synthase is well known, and is described in, for example, Julien et al., 2000, Isolation and characterization of the epothilone biosynthetic gene cluster from Sorangium cellulosum" Gene 249:153-60.
• the modular structure (domain organization) of the epothilone polyketide synthase is well known, and is described in, for example, Julien et al., 2000, Isolation and characterization of the epothilone biosynthetic gene cluster from Sorangium cellulosum" Gene 249:153-60.
• DNA sequence of the epothilone PKS is known and is set forth in, for example, U.S. patent no. 6,303,342 and in GenBank. [0404]
• the gene was designed by using a version of GeMS software developed. Modules were synthesized using Method R and Type II vectors. To synthesize the approximately 55 kb of DNA, the gene cluster was broken down into 118 synthon fragments ranging in size from 156 to 781 bp. The 3000 oligonucleotides were pooled into oligonucleotide mixtures using the Biomek FX and the assembly and amplification were performed using the conditions described in Example 1.
• EpoA SEQ ID NO: 6
• EpoB (SEQ ID NO: 7)
• EpoC (SEQ ID NO: 8)
• EpoD (SEQ ID NO: 9)
• EpoE (SEQ IDNO: 10)
• EXAMPLE 10 Synthetic genes correspondingto the geldanamycin polyketide synthase modules 0, 1 and 2 were designed and synthesized as described above (usingMethod S stitching). The sequences ofthe synthetic genes are shown below. The sequences ofthe corresponding naturally occurring genes are known (see, e.g., Rascher et al., 2003, Cloning and characterization ofa gene cluster for geldanamycin production in Streptomyces hygroscopicus NRRL 3602. FEMS Microbiology Letters 218:223-30 and PCTpublication WO03106653A2). Gdm Module 0 (Loading Module) (SEQ ID NO: 32)
• EXAMPLE 11 A synthetic gene corresponding to the oleandomycin polyketide synthase Loading Domain was designed and synthesized as described above (using Method S stitching). The sequence of the synthetic gene is shown below. The sequences of the corresponding naturally occurring genes are known (see GenBank accesion no. AF220951; also see Shah et al., 2000, "Cloning, characterization and heterologous expression of a polyketide synthase and P-450 oxidase involved in the biosynthesis of the antibiotic oleandomycin" J. Antibiot. 53:502-508).
• EXAMPLE 12 [0408] Synthetic genes corresponding to the picromycin polyketide synthase modules 2 and 6 and thioesterase (TE) were designed and synthesized as described above (using Method S stitching). The sequences of the synthetic genes are shown below. The sequences of the corresponding naturally occurring genes are known (see, U.S. Patent Nos. 6,303,767 and 6,117659).
• Pik module 2 (SEQ ID NO: 36)
• Pik module 6 (SEQ ID NO: 37)
• EXAMPLE 13 A synthetic gene corresponding to the HSP90 gene was designed and synthesized as described above (using Method S stitching). The sequence of the synthetic gene is shown below. The sequences of the corresponding naturally occurring gene is known (see, e.g., GenBank accession no:NM_005348; also see Yamazak et al. 1989, "Nucleotide sequence of a full-length cDNA for 90 kDa heat-shock protein from human peripheral blood lymphocytes" Nucleic Acids Res.
• HSP90 (SEQ ID NO:39) :
• CRMl (SEQ ID NO: 42) 1 MPAIMTMLAD HAARQLLDFS QKLDINLLDN VVNCLYHGEG AQQRMAQEVL THLKEHPDAW 61 TRVDTILEFS QNMNTKYYGL QILENVIKTR WKILPRNQCE GIKKYVVGLI IKTSSDPTCV 121 EKEKVYIGKL NMILVQILKQ EWPKHWPTFI SDIVGASRTS ESLCQNNMVI LKLLSEEVFD 181 FSSGQITQVK SKHLKDSMCN EFSQIFQLCQ FVMENSQNAP LVHATLETLL RFLN IPLGY 241 IFETKLISTL IYKFLNVPMF RNVSLKCLTE IAGVSVSQYE EQFVTLFTLT MMQLKQMLPL 301 NTNIRLAYSN GKDDEQNFIQ NLSLFLCTFL KEHDQLIEKR LNLRETLMEA LHYMLLVSEV 361

Landscapes

• Genetics & Genomics (AREA)
• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Chemical & Material Sciences (AREA)
• Biomedical Technology (AREA)
• Organic Chemistry (AREA)
• Wood Science & Technology (AREA)
• Biotechnology (AREA)
• General Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• Molecular Biology (AREA)
• Physics & Mathematics (AREA)
• Microbiology (AREA)
• Biophysics (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• Plant Pathology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Bioinformatics & Computational Biology (AREA)
• Ecology (AREA)
• Cell Biology (AREA)
• Micro-Organisms Or Cultivation Processes Thereof (AREA)
• Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
• Enzymes And Modification Thereof (AREA)

Priority Applications (2)

Applications Claiming Priority (2)

Publications (2)

Family

ID=35061024

Family Applications (1)

Country Status (4)

Cited By (9)

Families Citing this family (8)

Family Cites Families (12)

• 2004
  • 2004-04-07 US US10/820,975 patent/US20050227316A1/en not_active Abandoned
• 2005
  • 2005-04-05 JP JP2007507422A patent/JP2007533308A/ja not_active Withdrawn
  • 2005-04-05 WO PCT/US2005/011452 patent/WO2005103279A2/en not_active Ceased
  • 2005-04-05 EP EP05767675A patent/EP1740713A4/en not_active Withdrawn

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events